WO2004072018A1 - アミン誘導体 - Google Patents
アミン誘導体 Download PDFInfo
- Publication number
- WO2004072018A1 WO2004072018A1 PCT/JP2004/001467 JP2004001467W WO2004072018A1 WO 2004072018 A1 WO2004072018 A1 WO 2004072018A1 JP 2004001467 W JP2004001467 W JP 2004001467W WO 2004072018 A1 WO2004072018 A1 WO 2004072018A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- substituent
- alkyl
- ethyl
- reference example
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Definitions
- the present invention relates to an amine derivative which has an antagonistic action on melanin-concentrating hormone (hereinafter sometimes abbreviated as MCH) and is useful as an agent for preventing or treating obesity.
- MCH melanin-concentrating hormone
- Feeding behavior is an indispensable activity for many living things, including humans. For this reason, abnormalities in eating behavior often disrupt normal life activities and lead to disease.
- obesity has become a social problem with the changing dietary environment.
- Obesity is not only a significant risk factor for lifestyle-related diseases such as diabetes, hypertension, and atherosclerosis, but also weight gain can cause arthritis and pain by overloading knees and other joints. Is also widely known.
- many eating disorders such as bulimia caused by genetic or neurotic disorders such as stress have been reported.
- melanin-concentrating hormone is a hormone derived from the hypothalamus and is known to have an appetite-enhancing effect.
- MCH knockout mice have significantly reduced food consumption and light weight compared to normal mice, despite normal behavior.
- an MCH antagonist could be an excellent appetite suppressant or anti-obesity drug if possible.
- the following compounds are known as amine derivatives.
- Ar is an aromatic group which may have a substituent
- X and Y are the same or different
- R 8 is hydrogen An atom, a hydrocarbon group which may have a substituent or an acyl group) or a divalent de-e aliphatic hydrocarbon group which may contain one or two of these divalent groups;
- R 1 and R 2 may be a hydrogen atom or may have a substituent — represents 6 alkyl, and R 1 and R 2 may form a nitrogen-containing heterocyclic ring which may have a substituent together with an adjacent nitrogen atom.
- a ring does not represent a monocyclic aromatic ring which may further have a substituent], or a salt thereof (see WO 00/31 O21).
- Ar 1 is a cyclic group which may have a substituent; X is a spacer having 1 to 6 main chain atoms; Y is a bond or a spacer having 1 to 6 main chain atoms.
- Ar is a monocyclic aromatic ring which may be condensed with a 4- or 8-membered non-aromatic ring and may further have a substituent; R 1 and R 2 are the same or different and are each a hydrogen atom or substituted And R 1 and R 2 may form a nitrogen-containing heterocyclic ring which may have a substituent together with an adjacent nitrogen atom.
- 2 with Ar R 2 may form a nitrogen-containing heterocyclic ring which may have a substituent together with an adjacent nitrogen atom and Y) or a salt thereof. (See W001Z21577).
- Ar 1 is a cyclic group which may have a substituent
- X and Y are the same or different and each have a main chain having 1 to 6 atoms;
- Ar is a condensed polycyclic aromatic ring which may have a substituent;
- R 1 and R 2 may be the same or different and may have a hydrogen atom or a substituent, or may represent a hydrocarbon group, or R 1 and R 2 may have a substituent together with an adjacent nitrogen atom may form a nitrogen-containing heterocyclic ring, R 2 may form a nitrogen-containing heterocyclic ring which may have a substituent together with the nitrogen atom and Y adjacent, R 2 is adjacent nitrogen atom, May form a condensed ring together with Y and Ar] or a salt thereof (see W001 / 82925).
- Bz—X—Arg—MCA (Bz is a benzoyl group, MCA is 7-methylcoumarinamide, X is 4_aminomethyl-phenylalanine, 4-guanidine-phenylalanine, 4 (Indicating monoaminomethyl-N-isopropylphenylalanine and the like) (see Biochimi ca et Biophysica Acta, Vol. 1547, pp. 82-94, 2001).
- A is a straight-chain or branched alkylene having 2 to 5 carbon atoms
- Y is -N (R 4 ) (R 5 )
- R 4 and R 5 are the same or different and represent hydrogen, lower alkyl, acyl] or -OR 6
- R 6 is hydrogen, lower alkyl, aryl, acyl Show];
- R 1 is hydrogen, lower alkyl
- R 2 and R 3 are the same or different and form a heterocyclic ring with hydrogen, lower alkyl, aralkyl or an adjacent nitrogen atom;
- X represents hydrogen, halogen, or lower alkyl.
- R is amino, hydroxyl, lower alkoxy, acyloxy, aryloxy, acylamino, aryloyamino;
- A is lower alkylene;
- R 1 is hydrogen or acyl;
- R 2 is hydrogen or lower alkyl; Which represents a group that forms pyridine, 4-monosubstituted piperidine or 4-monosubstituted piperazine] or an acid addition salt thereof (see JP61-2663A).
- A is a straight-chain or branched alkylene having 2 to 5 carbon atoms
- W is -N (R 2 ) (R 8 ) [R 2 is hydrogen, lower alkyl; R 8 is hydrogen, acyl] or
- R 4 represents hydrogen, lower alkyl, aryl, or acyl]; R 1 is hydrogen, lower alkyl;
- R 5 and R 6 may be the same or different and may be hydrogen, lower alkyl, aralkyl or an adjacent nitrogen atom, together with 1-pyrrolidinyl, piperidino, 4-pyrubamoyl—4-piperidinopiperidino, 4-hydroxy-4-p- (p-tolyl) pi Peridino, morpholino, 4-substituted-1-piperazinyl;
- X represents hydrogen, halogen, lower alkyl] or a salt thereof (see JP51-141831A).
- Q represents a group X-Y [X represents an optionally substituted amino or the like; Y represents alkylene] or a heterocyclic ring;
- Z is an alkylene or the like
- R 1 and R 2 are hydrogen, halogen, alkyl, amino, nitro, hydroxyl;
- R 3 represents lower alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl] or a salt thereof (see JP2001 72660A).
- R is hydrogen, halo, Shiano, Shianoarukiru, alkyl, alkoxy, Fueno alkoxy, phenyl, alkoxy force Ruponiru, -NR 13 R 14, -N ( R!
- R 2 and R 3 are independently hydrogen, halo, alkyl, alkoxy, -NR 13 R 14 , halogenated alkoxy, halogenated alkyl, hydroxyl, -S (0) nR 7 or -NR 60 R 61 ;
- T is bound, 0, S, S0 2, carbonyl group, or 1, 3-Jiokisoran one 2- Iriden
- L 2 is alkylene, cycloalkylene or cycloalkylidene
- R 6 is hydrogen or (optionally substituted by alkoxycarbonyl or hydroxyl) alkyl
- Q is (optionally substituted with alkyl or hydroxyl) _ 9 alkylene chain
- Y is a salt of the compound or its represented by] represents an imidazole ring optionally substituted has been reported (TO95 / 00493 reference ). Disclosure of the invention
- An object of the present invention is to provide a compound having a melanin-concentrating hormone antagonistic activity and useful as an agent for preventing and treating obesity.
- the present inventors have conducted intensive studies on compounds having MCH antagonistic activity and found that
- Ar represents a monocyclic aromatic ring which may have a substituent
- Y represents an alkylene group which may be halogenated
- R 1 and R 2 are (1) the same or different, indicate hydrogen atoms or _ 6 alkyl Or (2) R 1 and R 2 form a nitrogen-containing heterocyclic ring which may have a substituent together with an adjacent nitrogen atom, or (3) R 1 and Y are substituted with an adjacent nitrogen atom have a group forming a nitrogen-containing heterocycle, R 2 represents a hydrogen atom or d_ 6 alkyl Le. ]
- Ar 1 represents a cyclic group which may have a substituent
- R represents a hydrogen atom, an optionally halogenated ( 6 alkyl, phenyl which may have a substituent or pyridyl which may have a substituent;
- Ra 1, Ra 2, Ra 3 and Ra 4 are the same or different, a hydrogen atom, halogenated optionally may _ 6 alkyl, phenyl which may have a substituent, a halogen atom, have a substituent and which may be pyridyl, Shiano, optionally halogenated or 6 alkoxy, optionally halogenated C, _ 6 alkylthio, amino, mono- primary or di-alkylamino, formyl, optionally halogenated Which represents an alkyl monosulfonyl or an alkylsulfonyl which may be halogenated).
- R 1 and R 2 are the same or different and each represent a hydrogen atom or an alkyl, or R 1 and R 2 together with an adjacent nitrogen atom form a nitrogen-containing heterocyclic ring which may have a substituent Compound (I);
- Ar 1 is a group represented by the formula: Ar 3 —Ar 2 — (wherein, Ar 2 represents a cyclic group which may have a substituent, and Ar 3 represents an aromatic ring group which may have a substituent )
- the compound (I) which is a group represented by:
- Y is - 6 alkylene group Compound (I);
- a melanin-concentrating hormone receptor antagonizing method in a mammal which comprises administering an effective amount of the compound (I) or a prodrug thereof to the mammal;
- 21 a method for preventing or treating a disease caused by melanin-concentrating hormone in a mammal, which comprises administering an effective amount of the compound (I) or a prodrug thereof to the mammal;
- a method for suppressing food intake in a mammal comprising administering an effective amount of compound (I) or a prodrug thereof to the mammal;
- 27 a method for preventing or treating depression in a mammal, which comprises administering an effective amount of the compound (I) or a prodrug thereof to a mammal; 28) producing a prophylactic or therapeutic agent for anxiety disorder Use of compound (I) or a prodrug thereof to perform
- a method for preventing or treating anxiety in a mammal which comprises administering an effective amount of compound (I) or a prodrug thereof to the mammal.
- an effective amount of compound (I) or a prodrug thereof to the mammal.
- cyclic group in the “optionally substituted cyclic group” represented by Arufaganma 1, an aromatic group, non-aromatic cyclic hydrocarbon group, such as a non-aromatic heterocyclic group .
- aromatic group includes a monocyclic aromatic group and a condensed polycyclic aromatic group.
- Examples of the monocyclic aromatic group include phenyl and a 5- or 6-membered aromatic heterocyclic group.
- Examples of the “5- or 6-membered aromatic heterocyclic group” include, for example, 5 or 6 containing one or more (eg, 1 to 3) heteroatoms selected from a nitrogen atom, a sulfur atom, and an oxygen atom in addition to a carbon atom. And a membered aromatic heterocyclic group. Specific examples include phenyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxadizazolyl, thiadiazolyl, and furazanyl.
- “monocyclic aromatic group” examples include phenyl, 2- or 3-phenyl, 2-, 3- or 4-pyridyl, 2- or 3-furyl, 2-, 4- or 5-thiazolyl, 2-, 4- or 5-oxazolyl, 1, 3- or 4-pyrazolyl, 2- Pyrazinyl, 2-, 4-mono- or 5-pyrimidinyl, 1-, 2- or 3-pyrrolyl, 1, 2- or 4-imidazolyl, 3- or 4-pyridazinyl, 3-, 4- or 5-isothiazolyl, 3-, 4- or 5-isoxazolyl, 1,2,4-oxazine diazole 5-yl, 1,2,4-oxazine diazole 3-yl, 1,3,4-oxazine diazole 2-yl.
- “Fused polycyclic aromatic group” is preferably a bicyclic to tetracyclic, more preferably a bicyclic or tricyclic aromatic group.
- Examples of the “condensed polycyclic aromatic group” include a condensed polycyclic aromatic hydrocarbon group, a condensed polycyclic aromatic heterocyclic group, and the like.
- Examples of the “condensed polycyclic aromatic hydrocarbon group” include, for example, a condensed polycyclic (2- or 3-cyclic) aromatic hydrocarbon group having 9 to 14 carbon atoms (eg, naphthalenyl, indenyl, fluorenyl, anthracenyl) Etc.).
- the “condensed polycyclic aromatic heterocyclic group” includes, for example, 9 to 14 containing one or more (for example, 1 to 4) heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to a carbon atom. And preferably 9- or 10-membered fused polycyclic '(preferably bi- or tricyclic) aromatic heterocyclic groups.
- the “fused polycyclic aromatic heterocyclic group” is more preferably a 10-membered fused polycyclic aromatic heterocyclic group.
- fused polycyclic aromatic heterocyclic group examples include benzochenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, naphtho [2,3-b] thiophenyl, Isoquinolyl, quinolyl, indolyl, quinoxalinyl, phenanthridinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, carbazolyl, 3-caprolyl, acrylinyl, phenazinyl, phthalimide, thitanyl, phthalimide
- fused polycyclic aromatic group examples include: 1- or 2-naphthyl; 2-, 31-, 4-, 5- or 8-quinolyl; 6-, 7- or 8-isoquinolyl; 1, 2-, 3-, 4-, 5-, 6- or 7-indolyl; 1-, 2-, 4- or 5-Isoindolyl; 1_, 5- or 6-phthalazinyl; 2-, 3- or 5-quinoxalinyl; 2-, 3-, 4-, 5- or 6-benzozoenyl; 2-, 3-, 4- , 51- or 6-benzofuranyl; 2-, 4-, 5- or 6-benzothiazolyl; 1, 2-, 41, 5- or 6-benzimidazolyl.
- non-aromatic cyclic hydrocarbon group for example, C 3 - 8 cycloalkyl, C 3
- non-aromatic heterocyclic group examples include a monocyclic non-aromatic heterocyclic group, a condensed polycyclic non-aromatic heterocyclic group, and the like.
- the “monocyclic non-aromatic heterocyclic group” includes, for example, a 5- to 8-membered member containing one or more (eg, 1 to 3) heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom in addition to a carbon atom. And a monocyclic non-aromatic heterocyclic group.
- tetrahydrothiophenyl tetrahydrofuranyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, vilazolinyl, vilazolidinyl, tetrahydrothiazolyl, tetrahydroisothiazolyl, tetrahydrooxazolyl, tetrahydroisoxazolyl, piperidinyl, tetrahydrozinyl Pyridyl, dihydropyridyl, piperazinyl, morpholinyl, thiomorpholinel, tetrahydropyrimidinyl, tetrahydropyridazinyl, hexamethyleneiminyl, dioxanyl and the like.
- the “fused polycyclic non-aromatic heterocyclic group” is preferably a bicyclic to tetracyclic, more preferably a bicyclic or tricyclic, nonaromatic heterocyclic group.
- the “fused polycyclic non-aromatic heterocyclic group” for example, one or more (for example, 1 to 4) hetero atoms selected from nitrogen, sulfur and oxygen atoms in addition to carbon atoms Containing 9 to 14 membered, preferably 9 or 10 membered fused polycyclic (preferably 2 or 3 ring) And a non-aromatic heterocyclic group.
- the ⁇ cyclic group '' represented by Ar 1 is preferably phenyl, a 5- or 6-membered aromatic heterocyclic group, a 5- to 8-membered monocyclic non-aromatic heterocyclic group, and more preferably phenyl. , Pyridyl, piperidinyl and the like.
- the “substituent” in the “optionally substituted cyclic group” represented by Ar 1 is, for example, a 'halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), a C x _3 alkyl Rangeoxy (eg, methylenedioxy, ethylenedioxy, etc.), nitrite, cyano, optionally halogenated C,.
- a 'halogen atom eg, fluorine, chlorine, bromine, iodine, etc.
- C x _3 alkyl Rangeoxy eg, methylenedioxy, ethylenedioxy, etc.
- nitrite eg, methylenedioxy, ethylenedioxy, etc.
- cyano optionally halogenated C
- Alkyl, hydroxy-- 1Q alkyl eg, hydroxymethyl, hydroxyethyl E chill
- C Bok 6 alkyl e.g., such as Fuenokishimechiru
- C ⁇ _ 6 alkyl one C 6 _ 4 Ariru one C 2 _ 6 alkenyl e.g., methyl phenylalanine E butenyl
- an optionally halogenated C ⁇ alkoxy halogenated which may be C chi _ 10 alkylthio, which may have a substituent C 7 _ 1 9 Ararukiru, hydroxy, optionally substituted C 6 - 1 4 Ariruokishi, but it may also have a substituent group C 7 - 1 9 Ararukiruokishi
- Amino, Amino one C 1 () alkyl For example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, etc.), mono- or di-C ⁇ .
- Alkylamino eg, methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, Puropiruamino, Jibuchiruamino, such as E chill methyl ⁇ Mino
- mono- or di-C 10 alkylamino over C Bok 6 alkyl e.g., methylaminomethyl, Echiru aminomethyl, propyl-aminomethyl, Butyl aminaminonoethylmethyl, didimethytylluaminominometyl, dijetitylluaminominometyl, dizipropropipirul
- Acyclic cyclic group represented by AArr 11 is the same as the above, except that the above-mentioned substitutional substituent is replaced with a substituent capable of substitution with the cyclic cyclic group. There may be 11 or 55 in the position, or 11 or 33 in good condition. . When the number of the substituent groups is 22 or more, even if each of the substituent groups is the same as each other, It may be different. .
- halologogenogen CC 1155 As described above, "" It may be converted into a halologogenogen CC 11. It may be aralkikirul. "For example, for example, 11 or 55 pieces, , Or 11 or 33 hahalogenogen atoms (e.g., fluorine, chlorine chloride, bromobromide, iodine, etc. )) That may have CC ,,. .
- Aarukikiruru (eg, Memethytyl, Ethityl, Pupropropylu, Iisosopprolopipir, Bubutyril, Iisosobbutyril, sseecc-Bubutyril, tteerr tt—Bubutytyl, Penpentyl Hexylsilyl, hehepeptyril, okoctylyl, nononinyl, dedecisyl, etc.)
- Specific examples of the specific examples include: methitityl, chlorochloromethytyl, didifluorofluoromethytyl, totriliclochloromethytyl, totririfulolomethytyl, , ⁇ eti ⁇ ⁇ l ⁇ l, 22——B ⁇ ⁇ bulomomo ⁇ eti ⁇ l ⁇ l, 22,, 22,22, 22—T ⁇ ⁇ trif ⁇ ⁇ l ⁇ l ⁇ ⁇ ⁇ ⁇ , 33 ,, 33 ,, 33——Totryrifflurololopropiropil, Iisosopproropipirul, Bubutytyl, 44 ,, 44 ,, 44__Totririfflurorollobuchitill ,,,, Sseecc, butyl,, tteerr tt-bubutyril,, pepenticyl,,,,,,,
- CC which can be converted into hahalogenogenation CC
- .. Aarulcocoxixi is, for example, 11 or 55. 11 or 33 or 33 hahalogenogen atoms (e.g., fluorinated, chlorinated, brominated, iodinated, etc.) )
- hahalogenogen atoms e.g., fluorinated, chlorinated, brominated, iodinated, etc.
- Aarul cocoxixi e.g., Toxic, propoxy, butoxy, pentyloxy, hexyloxy, heptoxy, octyloxy, nonyloxy, decyloxy, etc.
- Specific examples include, for example, methoxy, difluoromethoxy, trifluoromethoxy, ethoxy, 2,2,2-trifluoroethoxy, propoxy, 'isopropoxy, butoxy, 4,4,4-trifluorobutoxy, isobutoxy And secec-butoxy, pentyloxy, isopentyloxy, hexyloxy, heptyloxy, octyloxy, nonyloxy, decyloxy and the like.
- the “optionally halogenated C. alkylthio” includes, for example, 1 to 5, preferably 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.). May be C,. And alkylthio (eg, methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio, pentylthio, hexylthio, heptylthio, octylthio, nonylthio, decylthio, etc.).
- alkylthio eg, methylthio, ethylthio, propylthio, isopropylthio, butylthio, sec-butylthio, tert-butylthio, pentylthio, hexylthio, heptylthi
- Specific examples include, for example, methylthio, difluoromethylthio, trifluoromethylthio, ethylthio, propylthio, isopropylthio, butylthio, 4,4,4-trifluorobutylthio, pentylthio, hexylthio, heptylthio, octylthio, and noelthio. And decylthio.
- C 7 _ 1 9 ⁇ aralkyl in the "optionally C 9 Ararukiru be substituted", for example, benzyl, phenethyl, Jifuenirumechiru, Bok riffs enyl methyl, 1 one naphthylmethyl, 2-naphthylmethyl , 2,2-diphenylethyl, 3-phenylpropyl, 4-phenylbutyl, 5-phenylpentyl and the like.
- the Ararukiruokishi ", for example, Benjiruokishi, Fuenechiruo alkoxy, Jifue two Rumechiruokishi, Bok riff enyl methyl O alkoxy, 1 one Nafuchirume Tiloxy, 2-naphthylmethyloxy, 2,2-diphenylethyloxy, 3-phenylpropyloxy, 4-phenylbutyloxy, 5-phenylpentyloxy, and the like.
- the “aromatic ring group” in the “aromatic ring group optionally having substituent (s)” the “aromatic group” exemplified as the aforementioned Ar 1 can be mentioned.
- the “aromatic ring group” is preferably phenyl, naphthyl, a 5- or 6-membered aromatic heterocyclic group, a 9- or 10-membered condensed polycyclic aromatic heterocyclic group, and more preferably, phenyl, 5 Or a 6-membered aromatic heterocyclic group. Of these, phenyl, pyridyl and the like are preferred.
- non-aromatic ring group in the “non-aromatic ring group optionally having substituent (s)
- non-aromatic cyclic hydrocarbon group and “non-aromatic heterocyclic ring” exemplified as Ar 1 above Group ".
- C 3 _ 6 cycloalkyl - C ⁇ 6 alkyl in “C 3 - 6 cycloalkyl - C Medicine 6 alkyl” includes, for example, cyclopropylmethyl, cyclopropyl E chill, Cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, and the like.
- C 3 _ 6 may be a cycloalkyl one C Bok 6 alkoxy substituted" -
- the "C 3 6 cycloalkyl one C DOO 6 alkoxy” for example consequent opening Puropirume Bok alkoxy, cyclopropylethoxy , Cyclobutylmethoxy, cyclobutylethoxy, cyclopentylmethoxy, cyclopentylethoxy, cyclohexylmethoxy, cyclohexylethoxy, cyclohexylpropoxy and the like.
- C alkoxy-C alkoxy examples include methoxy methoxy, methoxy ethoxy, ethoxy methoxy, ethoxy ethoxy and the like.
- Alkyl hydroxy-cu alkyl (e.g., hydroxy Shimechiru, hydroxy E chill), optionally halogenated C 3 - 6 Shikuroa alkyl, optionally halogenated c,. Alkoxy, optionally halogenated C 1D alkylthio, hydroxy, amino, mono or gee C!
- 10- alkylamino eg, methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, acetylamino, zippyramino, dibutylamino, ethylmethylamino, etc.
- amino-C1 ⁇ alkyl eg, aminomethyl, aminoethyl, Aminopropyl, aminobutyl etc.
- mono or di-C mono or di-C
- Alkylamino—C ⁇ 6 alkyl eg, methyl aminomethyl, ethylaminomethyl, propylaminomethyl, isopropylaminoethyl, butylaminoethyl, dimethylaminomethyl, getylaminomethyl, dipropylaminomethyl, disopropylaminoethyl, Dibutylaminoethyl, etc.
- formyl propyloxy, pylbamoyl, thiocarbamoyl, optionally halogenated C ⁇ 6 alkyl-pyruponyl, 6 -alkoxy monophyllonyl (eg, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl) , Tert-butoxycarbonyl, etc.), 5- to 6-membered heterocyclic carbonyl, mono- or di-C ⁇ 6 alkyl monorubumoyl (eg, methylcarbamoyl, e
- the "optionally halogenated and C 3 - 6 cycloalkyl” includes, For example, 1 to 5, preferably 1 to 3 halogen atoms (e.g., fluorine, salt Iodine, bromine, optionally C 3 _ 6 cycloalkyl (eg have a iodine), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexylene hexyl etc.) and the like.
- 1 to 3 halogen atoms e.g., fluorine, salt Iodine, bromine
- C 3 _ 6 cycloalkyl eg have a iodine
- cyclopropyl cyclobutyl
- cyclopentyl cyclohexylene hexyl etc.
- cyclopropyl cyclobutyl, cyclopentyl, cyclohexyl, 4,4-dichlorocyclohexyl, 2,2,3,3-tetrafluorocyclopentyl, 4-chlorocyclohexyl and the like.
- Examples of the “optionally halogenated C 6 alkyl-alkenyl” include 1 to 5, preferably 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.).
- Ci- 6 alkyl monopropionyl eg, acetyl, propanoyl, 2-methylpropanol, butanol, 3-methylbutanoyl, pentanoyl, hexanoyl, etc.).
- acetyl monochloroacetyl, trifluoroacetyl, trichloroacetyl, propanol, 2-methylpropanoyl, butanol, 3-methylbutanol, pentanoyl, hexanoyl, and the like.
- Examples of the “5- to 6-membered heterocyclic carbamoyl” in the above “5- to 6-membered heterocyclic carbamoyl” and “5 to 6-membered heterocyclic carbamoyl—C ⁇ 6 alkyl” include, for example, morpholinocarbamoyl, piperidino Carbamoyl, 1-pyrrolidinylcarbamoyl, 2-pyridylcarbamoyl, 3-pyridylcarbamoyl, 4-pyridylcarbamoyl, 2-chernylcarbamoyl, 3-chenylcar Bamoyl and the like.
- Examples of the “5- to 6-membered heterocyclic rubamoyl-C alkyl” include morpholino rubamoylmethyl, morpholino rubamoylethyl, morpholinocarbamoylpropyl, piperidinocarbamoylmethyl, piperidinocarbamoylethyl, piperidinocarbamoylpropyl, 1-pyrrolidinyl Carbamoylmethyl, 1-pyrrolidinylcarbamoylethyl, 1-pyrrolidinylcarbamoylpropyl and the like.
- the “optionally halogenated C 6 alkylsulfonyl” includes, for example, 1 to 5, preferably 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.).
- C.sub.i- 6 alkylsulfonyl eg, methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl, etc.
- Specific examples include methylsulfonyl, difluoromethylsulfonyl, trifluorosulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, 4,4,4-trifluorobutylsulfonyl, pentylsulfonyl, hexylsulfonyl Honyl and the like.
- Examples of the “optionally halogenated C alkyl monofunctional lipoxamide” include, for example, 1 to 5, preferably 1 to 3 halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.). And C 6 alkyl-carboxamides (eg, acetoamide, propanamide, butanamide, etc.) which may be used. Specific examples include, for example, acetoamide, trifluoroacetamide, propanamide, butanamide and the like.
- acyl exemplified as the “substituent” in the above Ar 1 include, for example, the following formulas: —CO—R 3 , —CO—OR 3 , C 0 _NR 3 R 4 , C CS —NR3 ⁇ 4 4 , —S0 2 — R 3, one S0- R 3, _P0 (- oR 3) - oR 4 or - P0 2 - R 3 wherein the (i) a hydrogen atom, (ii) a substituted hydrocarbon which may have a substituent R 3 represents a hydrogen atom or C 6 alkyl; and R 3 and R 4 have a substituent together with an adjacent nitrogen atom. May form a nitrogen-containing heterocyclic ring And a group represented by the formula:
- hydrocarbon group in the “optionally substituted hydrocarbon group” for R 3 examples include, for example, a linear or cyclic hydrocarbon group (eg, alkyl, alkenyl, alkynyl, cycloalkyl , Aryl, aralkyl, cycloalkylalkyl, etc.). Among them, the following linear or cyclic hydrocarbon groups having 1 to 19 carbon atoms are preferred. Further, the cycloalkyl and the cycloalkyl in the cycloalkylalkyl may be condensed with a benzene ring.
- C Bok 6 alkyl e.g., methyl, Echiru, propyl, isopropyl, butyl Le, isobutyl, sec- butyl, ter t-butyl, pentyl, hexyl, etc.
- C 2 _ 6 alkenyl e.g., Biel, Aryl, isoprobenyl, 2-butenyl, etc.
- C 2 - 6 alkynyl e.g., Echiniru, propargyl, 2-butynyl, etc.
- d) fused to a benzene ring optionally C 3 - 6 cycloalkyl e.g., Shikurobu port pills, cyclobutyl, cyclopentyl, cyclohexylene Xyl
- C 3 - 6 cycloalkyl e.g., Shikurobu port pills, cyclobutyl, cyclopentyl, cyclohexylene Xyl
- Ariru e.g., phenyl, 1-naphthyl, 2-naphthyl, 2-in-denier, such as 2 _ anthryl
- a benzene ring fused or unprotected C 3 _ 6 cycloalkyl - C ⁇ 6 alkyl e.g., cyclopropylmethyl, cyclopropyl E chill, Shikuropuchirumechi Le, cyclopentylmethyl, cyclopentyl Rue chill, cyclohexane Kishirupuropi Le etc.
- Hydrocarbon group is preferably a C ⁇ 6 alkyl, c 6 _ 1 4 Ariru, c 7 _ 1 9 Ararukiru, fused to a benzene ring which may be C 3 -6 cycloalkyl, benzene ring fused which may be C 3 _ 6 cycloalkyl - C i-6 alkyl, and the like.
- substituted in the above “hydrocarbon group which may have a substituent” Is, for example, a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), alkylenedioxy (eg, methylenedioxy, ethylenedioxy, etc.), nitro, cyano, optionally halogenated C 4.
- a halogen atom eg, fluorine, chlorine, bromine, iodine, etc.
- alkylenedioxy eg, methylenedioxy, ethylenedioxy, etc.
- nitro cyano
- the “optionally halogenated C ,. alkoxy” and the “optionally halogenated C. alkylthio” may each have a “substituent which may be represented by the aforementioned Ar 1 What is illustrated as “substituent” in "cyclic group” is used.
- Examples of the “5- to 10-membered aromatic heterocyclic group” in the “optionally substituted 5- to 10-membered aromatic heterocyclic group” include, for example, a nitrogen atom, a sulfur atom and an oxygen atom other than a carbon atom. Examples thereof include a 5- to 10-membered monocyclic or bicyclic aromatic heterocyclic group containing 1 to 4 heteroatoms selected from atoms.
- C 6 _ 1 4 Ariru Ichiriki Ruponiru in the “optionally optionally C 6 _ 1 4 Ariru one carbonyl which may have a substituent", for example, Benzoiru, 1-naphthyl Bok I le, 2-naphthoyl, etc. Is mentioned.
- definitive "c 6 _ 1 4 Ariruokishi Ichiriki Ruponiru” to "have a good C 1 4 Ariruokishi Ichiriki Ruponiru may have a substituent", for example Fueniruo alkoxycarbonyl, 1-naphthyl O alkoxycarbonyl, 2-naphthyl Oxycarbonyl and the like.
- C 7 - 1 9 Ararukiruokishi Ichiriki Ruponiru in - as the "C 7 1 9 Ararukiruokishi Ichiriki Ruponiru
- benzyl O carboxymethyl Cal Poni Le Hue phenethyl Ruo alkoxycarbonyl, Diphenylmethyloxycarbonyl, triphenylmethyloxycarbonyl, 1-naphthylmethyloxycarbonyl, 2-naphthylmethyloxycarbonyl, 2,2-diphenylethyloxycarbonyl, 3-phenylpropyloxycarbonyl, 4 Monophenylbutyloxycarbonyl, 5-phenylphenyloxycarbonyl and the like.
- the “5- or 6-membered heterocyclic ruponyl which may have a substituent” may be C 7 which may have a substituent - 1 9 Ararukiru "" Ru used those exemplified as the substituent "in. '
- c 6 _ 14 aryl-carbamoyl optionally having substituent (s) includes, for example, phenylcarbamoyl, 11-naphthylcarbamoyl , 2-naphthylcarbamoyl and the like.
- the “5- to 6-membered heterocyclic rubamoyl” in the “5 to 6-membered heterocyclic rubamoyl optionally having a substituent” includes the “C 9 aralkyl optionally having a substituent”.
- the above-mentioned "substituents" are used.
- the ⁇ reel sulfonyl for example, phenylalanine sulfonyl, 1 over Na Fuchirusuruhoniru, such as 2-naphthylsulfonyl and the like.
- Examples of the “5- to 6-membered heterocyclic alkoxyl” in the “optionally substituted 5- or 6-membered heterocyclic alkoxyl” include, for example, nicotinyloxy, isonicotinoyloxy, 2-tenoloxy, Examples include 3-thenoyloxy, 2-fluoroyloxy, 3-fluoroyloxy, morpholinocarbonyloxy, piperidinocarbonyloxy, and pyrrolidine-1-ylcarponyloxy.
- heterocyclic group in the “optionally substituted heterocyclic group” for R 3 , for example, in addition to a carbon atom, one to four heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom 5- to 14-membered (monocyclic, bicyclic or tricyclic) heterocyclic group containing a telo atom, preferably (i) an aromatic heterocyclic group, (ii) a 5- to 10-membered non-aromatic heterocyclic group or (iii) And a 7- to 10-membered bridged heterocyclic group.
- aromatic heterocyclic group includes, for example, a 5- to 14-membered member containing one or more (for example, 1 to 4) heteroatoms selected from nitrogen, sulfur and oxygen atoms in addition to carbon atoms.
- Preferable examples include a 5- to 10-membered aromatic heterocyclic group.
- Examples of the “5- to 10-membered non-aromatic heterocyclic group” include, for example, pyrrolidinyl, imidazolidinyl, 2- or 4-dimidazolinyl, 2-oxazolinyl, oxazolidinyl, 2- or 3-pyrazolinyl, pyrazolidinyl, 2-thiazolinyl , Piperidinyl, piperazinyl, hexamethyleneiminyl, morpholinyl, thiomorpholinyl and the like.
- Examples of the "7- to 10-membered bridged heterocyclic group” include quinuclidinyl, 7-azabizik [2.2.1] hepnyl, and the like.
- heterocyclic group is preferably a 5- to 10-membered (monocyclic or bicyclic) which contains, in addition to carbon atoms, 1 to 4 heteroatoms selected from nitrogen, sulfur and oxygen.
- Formula) is a heterocyclic group, specific examples of which are 2 or 3 phenyl; 2-, 3- or 4-pyridyl; 2- or 3-furyl; 2-, 4- or 5-thiazolyl; —, 4- or 5-oxazolyl; 1,3- or 4-pyrazolyl; 2-pyrazinyl; 2-, 4- or 5-pyrimidinyl; 1-, 2- or 3-pi 1,2-, 4- or 4-imidazolyl; 3- or 4-pyridazinyl; 3-isothiazolyl; 3-isoxazolyl; 1,2,4-oxadiazolyl 5-yl; 1,2,4-oxadiazolyl 3-yl 2-, 3-, 4-, 5- or 8-quinolyl; 1, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl; 1, 2-
- Examples of the “substituent” in the “optionally substituted heterocyclic group” include those exemplified as the “substituent” in the above “optionally substituted C 9 aralkyl”. Used.
- the number of substituents is, for example, 1 to 5, preferably 1 to 3. When the number of substituents is two or more, each substituent may be the same or different.
- the “( ⁇ -6 alkyl)” represented by R 4 includes, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.
- the "substituent" in the "nitrogen-containing heterocyclic ring which may be substituted” the "optionally substituted C 7 - 1 9 Ararukiru” exemplified as the “substituent” in Things are used.
- the number of substituents is, for example, 1 to 5, preferably 1 to 3. When the number of substituents is two or more, each substituent may be the same or different.
- the substituent is preferably c alkyl which may be halogenated, ⁇ 6 alkylsulfonyl which may be halogenated, and the like.
- the “acyl” is formyl, carboxy, carbamoyl, optionally halogenated C 6 alkyl-carbonyl (eg, acetyl, propanol, 2-methylpropanol, butanol, 3 -Methylbutanol, pentanoyl, hexanoyl, etc.), C ⁇ 6-alkoxy-carbonyl (eg, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, tert-butoxycarbonyl, etc.), optionally substituted C 6 _ 1 4 ⁇ Li Ichiru - carbonylation Le (eg, Benzoiru, 1 one naphthoyl, 2-naphthoyl), which may have a substituent C 6 _ 1 4 Ariruokishi Ichiriki Ruponiru (e.g., phenyl Okishikaru Poniru, 1 one naphthyl O carboxymethyl Cal Poni
- Tetorahi Dorofuroiru mono- or Di-C 6 alkyl monorubumoyl (eg, methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, methylcarbamoyl, ethylmethylcarbamoyl, etc.), which may have a substituent C 6 — 14 aryl-carbamoyl (eg, phenylcarbamoyl, 4-methoxyphenylcarbamoyl, 3,4-dimethylmethoxycarbamoyl, etc.), optionally substituted 5- to 6-membered heterocyclic ring C 6 _ 1 , optionally substituted halogenated C- 6 alkylsulfonyl (eg, methylsulfonyl, propylsulfonyl, butylsulfonyl, etc.), optionally substituted C 6 _ 1 4 ⁇ Li one Rusuruhoni
- Kishirukaruponiru have a substituent and optionally C 3 - 6 cycloalkyl - C Bok 6 alkyl one carbonyl (e.g., cyclopropylmethyl Cal Poni Le, cyclo B pills E Chiruka Lupo sulfonyl, Shikuropen chill methyl Cal Poni Le, cyclohexane, etc. cyclohexyl methyl Cal Poni Le) and the like.
- the “optionally halogenated C ⁇ 6 alkyl-caprolponyl” and the “optionally halogenated C ⁇ 6 alkylsulfonyl” are respectively the above-mentioned “having a substituent”. those exemplified as the "substituent” is used in 1 9 Ararukiru "- which may C 7 to.
- Optionally substituted C 6 - 1 4 Ariru - Power Ruponiru "optionally substituted c 6 - 1 4 Ariruokishi - Power Ruponiru”, have a "substituent C 7 — 1 9 aralkyloxy monofunctional rubonyl ”,“ optionally substituted 5- or 6-membered heterocyclic carbonyl ”,“ optionally substituted C 6 — 14 aryl— power Rubamoiru ", as” 5- or substituted 6-membered multiple ring power Rubamoiru “and” optionally substituted C 6 _ 1 4 Arirusuru Honiru “as the R 4 Examples of the “substituent” in the “hydrocarbon group which may have a substituent” shown are used.
- substituents in the "optionally substituted C 3 - 6 cycloalkyl Ichiriki Ruponiru” and “force Ruponiru may have a location substituent C 3 _ 6 Shikuroarukirire - - C ⁇ 6 alkyl”
- substituents those exemplified as “substituent” in the above “ 9- aralkyl optionally having substituent (s)” are used.
- the number of substituents is, for example, 1 to 3. When the number of substituents is two or more, each substituent may be the same or different.
- acylamino examples include, for example, an amino substituted with one or two of the above “acyl”, preferably a compound represented by the formula: 1 NR 5 —C0R 6 one NR 5 - C00R 6, one NR 5 - S0 2 R 6, one NR 5 - CONR 6 R 7, - NR 5 -PO (- O 6) - oR 7 or a NR 5 - P0 2 - R 6 [ wherein, R 5 is a hydrogen atom or a (; ⁇ _ 6 alkyl; R 6 is the R 3 the same meanings; R 7 is like ⁇ shea Ruamino represented by the same significance as R 4].
- R 5 - Represented by R 5 - as "( ⁇ 6 alkyl", those exemplified for the aforementioned R 4 are exemplified up.
- the “acylamino” is formylamino, C ⁇ 6 alkyl-carpoxamide (eg, methylcarpoxamide, trifluoromethylcarpoxamide, propylcarpoxamide, isopropylcarpoxamide, which may be octalogenated).
- C ⁇ 6 alkyl-carpoxamide eg, methylcarpoxamide, trifluoromethylcarpoxamide, propylcarpoxamide, isopropylcarpoxamide, which may be octalogenated.
- N-C 6 alkylamino e.g., such as N-4 over methoxybenzoyl I le -N- Mechiruamino
- substituted C 9 aralkyl optionally having lipoxamide (eg, benzyl Rukarupokisamido etc.)
- an aromatic heterocyclic Ichiriki optionally having substituent Rupokisamido (e.g., such as Benzochio phen one 2-I Luca Lupo alkylcarboxamide), optionally halogenated and C Bok 6 alkoxy Ichiriki Rupokisamido (Eg, methoxycarboxamide, ethoxycarpoxamide, propoxycarpoxamide, butoxycarpoxamide, etc.), which may have a substituent C 6 _ 14 arylamine carbonylamino (eg, phenylaminoamino)
- C 6 _ 14 arylamine carbonylamino e.g, phenylamino
- C 6 _ 14 aryl-1 carboxamide optionally having a substituent “N- (which may have a substituent C 6 _ 1 4 7 reel one carbonyl) - N-C Medicine 6 Arukiruamino", “optionally substituted C 7 one 1 9 Ararukiru Ichiriki Rupokisamido "," aromatic heterocyclic Ichiriki Rupokisami de be substituted “,” optionally substituted C 6 _ 1 4 ⁇ arylamino over local Poni Le amino "and” substituted group the "substituent” in “the substituent”, the "optionally substituted C 7 9 ⁇ La alkyl” in 1 4 ⁇ reel sulfonyl ⁇ amino "- have a good C 6 have a Examples are given.
- the number of substituents is, for example, 1 to 5 ⁇ , preferably 1 to 3. When the number of substituents is two or more, each substituent may be the same or different.
- acylsoxy examples include, for example, oxy substituted by one piece of the above “acyls”, and preferably have the formulas: 10 — C0R 8 , —0 — C00R 8 , — 0—CO thigh 8 , — 0— PO (OH) —OR 8 or — 0— PO 2 — R 8 (wherein, R 8 has the same meaning as R 3 above).
- the "Ashiruokishi" preferably optionally C! _ 6 alkyl Ichiriki Ruponiruokishi be halogenated (eg, Asetokishi, prop noisy Ruo carboxymethyl, etc. butano Iruokishi), optionally C 6 optionally having substituent - 1 4 Ariru Ichiriki Ruponiru Okishi (eg, Benzoiruokishi, 4-methoxybenzoyl I Ruo carboxymethyl, etc.), halogenation which may be C bets 6 alkoxy Ichiriki Ruponiruokishi (e.g., methoxy force Ruponiruokishi, triflumizole Ruo b methoxy local Poni Le Methoxy, ethoxycarpoxy, propoxyloxyloxy, butoxycarpoxyloxy, etc.), mono or di-C ⁇ 6 alkyl monocarboxylic acid rubamoyloxy (eg, methylcarbamoyloxy,
- acyl-C ⁇ 6 alkyl examples include “acyl-C ⁇ 6 alkyl”, “acylamino-C 6 alkyl” and “acyloxy C 6 alkyl” exemplified as the “substituent” in Ar 1 are the “acyl” “acylamino” or “acyloxy”, respectively.
- C ⁇ 6 alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.
- the “substituent” in the “optionally substituted cyclic group” represented by Ar 1 is preferably a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), 3 alkylenedioxy (eg, methylenedioxy) , Ethylenedioxy, etc.), nitro, cyano, optionally halogenated C.
- halogen atom eg, fluorine, chlorine, bromine, iodine, etc.
- 3 alkylenedioxy eg, methylenedioxy
- Ethylenedioxy etc.
- nitro, cyano optionally halogenated C.
- Alkoxy which may have a substituent c 6 _ u Ariruoki sheet, which may have a substituent c 7 one 19 Ararukiruokishi, which may have a substituent C 3 _ 6 cycloalkyl - C 6 alkyl, optionally substituted C 3
- _ 6 cycloalkyl one C ⁇ 6 alkoxy, Ashiru, Ashiru -C ⁇ 6 alkyl, human Dorokishi, C 6 alkoxy one C physician 6 alkoxy, C WINCH but it may also be halogenated. Alkylthio, acylamino, acyloxy, acyl— ( ⁇ -6 alkyl, etc.
- Ar 1 is preferably a compound represented by the formula: Ar 3 _Ar 2 _ (wherein, Ar 2 represents a cyclic group which may have a substituent, and Ar 3 represents an aromatic ring group which may have a substituent. Is shown).
- the “cyclic group” in the “optionally substituted cyclic group” represented by Ar 2 the “aromatic group” exemplified as the aforementioned Ar 1 , the “non-aromatic cyclic hydrocarbon group” And “a non-aromatic heterocyclic group”.
- the “cyclic group” is preferably Phenyl, a 5- or 6-membered aromatic heterocyclic group, a 5- to 8-membered monocyclic non-aromatic heterocyclic group, and more preferably phenyl, pyridyl, piberidinyl and the like. '
- substituents in the “optionally substituted cyclic group” represented by Ar 2 may include those exemplified as the substituent in the Ar 1.
- the number of the substituents is, for example, 1 to 4, preferably 1 to 3. When the number of substituents is two or more, each substituent may be the same or different.
- the substituent is preferably a halogen atom (preferably fluorine, chlorine and the like), a C 6 alkyl which may be halogenated (preferably methyl, trifluoromethyl, ethyl and the like).
- aromatic ring group examples include those exemplified as the “substituents” in the aforementioned “optionally substituted cyclic group” for Ar 1 Is mentioned.
- aromatic ring group is preferably phenyl, naphthyl, a 5- or 6-membered aromatic heterocyclic group, a 9- or 10-membered condensed polycyclic aromatic complex group, and more preferably phenyl. And a 5- or 6-membered aromatic heterocyclic group. Of these, phenyl, pyridyl and the like are preferred.
- the “aromatic ring group” may have, for example, 1 to 4, preferably 1 to 3 substituents at substitutable positions.
- substituents such as the "optionally C 7 optionally having substituent - 1 9 Ararukiru” those exemplified as the "substituent” in the like.
- a halogen atom preferably, fluorine, chlorine, etc.
- C bets 6 alkyl which may be halogenated (preferably methylation, Bok Rifuruoromechiru, etc.
- C chi be halogenated _ 6 alkoxy (preferably methoxy, trifluoromethoxy, etc.), optionally halogenated C ⁇ 6 alkylthio (preferably methylthio, etc.), C ⁇ 3 alkylenedioxy (preferably methylenedioxy, ethylenedioxy ), Optionally halogenated C 6 alkyl-carponyl (preferably, acetyl, etc.), and optionally halogenated C 6 alkyl mono-l-poxamide (preferably, isopropyl carboxamide, etc.). preferable.
- Ar 3 Ar 2 — (the symbols in the formula are as defined above)
- Specific examples of the group include 2-, 3- or 4-biphenylyl which may have 1 to 3 substituents; 3- (1-naphthyl) _1,2,4-oxaziazo 3- (2-naphthyl) -1-1,2,4-oxadiazol-5-yl; 3- (2-benzofuranyl) -1-1,2,4-oxadiazol-5-yl 3_phenyl-1,2,4-oxaziazolyl 5-yl; 3_ (2-benzoxazolyl) -1 1,2,4-oxadiazol-5-yl; 3— (3-indolyl) -1,2,4-oxaziazol-5-yl; 3- (2-indolyl) -1,2,4-oxaziazol-5-yl; —phenylthiazole-2-yl; 4_ (2 4-Benzofuranyl) thiazole
- substituents include a halogen atom (preferably, fluorine, chlorine, etc.), _ 6 alkyl which may be halogenated c t (preferably methylation, Bok Rifuruoromechiru, etc. Echiru)
- halogenated C preferably, fluorine, chlorine, etc.
- _ 6 alkyl which may be halogenated c t (preferably methylation, Bok Rifuruoromechiru, etc. Echiru)
- halogen optionally halogenated C alkylthio (preferably, methylthio, etc.), C ⁇ alkylenedioxy (preferably, methylenedioxy, ethylenedioxy, etc.), optionally halogenated C 6 alkyl monoalkyl propyl ( Preferable examples include acetyl, etc.), and optionally halogenated Ci-6 alkyl-hexyl poloxamide (preferably, isopropyl carpoxamide, etc.).
- Ar 1 examples include a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), C ⁇ 3 alkylenedioxy (eg, methylenedioxy, ethylenedioxy, etc.), nitro, cyano, halogenated Good C ,.
- halogen atom eg, fluorine, chlorine, bromine, iodine, etc.
- C ⁇ 3 alkylenedioxy eg, methylenedioxy, ethylenedioxy, etc.
- nitro, cyano, halogenated Good C e.g, fluorine, chlorine, bromine, iodine, etc.
- Alkyl eg, methyl, ethyl, propyl, butyl, pentyl
- optionally halogenated carbon Alkoxy (eg, methoxy, ethoxy, propoxy, butoxy, isobutoxy, ⁇ , pentyloxy, isopentyloxy, etc.) and substituents (preferably halogen, optionally halogenated C, alkyl, halogenated have a well as good C 10 Arirekokishi) unprotected c 6 - 14 ⁇ Li -.
- Ruokishi preferably phenoxy
- substituent preferably a halogen atom, an optionally halogenated c, alkyl, Optionally halogenated C
- alkyl C 3 monoalkyl (s) which may have a halogenated C, alkoxy, etc.) — C 6 alkoxy (preferably cyclopropylmethoxy, cyclopropylethoxy), acyl [preferably Is an optionally halogenated C ⁇ 6 alkyl monocarbonyl (eg, pentanoyl, hexanoyl, etc.), C 6 alkylsulfonyl (eg, butylsulfonyl, etc.)], acyl-C alkyl (preferably optionally halogenated C ⁇ 6 alkyl monophenyl CHalkyl (eg, propanoy) Methyl, propanoylethyl, 2-methylpropano Irumechiru, Butasoirumechiru, 3 - Mechirubu evening Noirumechiru, pen evening Noiru methyl), halogenated one good C alkylsulfonyl also be C i - 6 al
- Alkylthio preferably, methylthio, butylthio, etc.
- acylamino preferably optionally halogenated C 6 alkyl-caprolamide (eg, propylcarboxamide, isopropylcaprolamide, butylcarboxamide, etc.
- a substituent preferably, C DOO 6 alkyl Ichiriki Lupo two Lou C E alkyl
- C 6 _ 1 4 have a re one Luca Lupo alkylcarboxamide (preferably phenylene Rukarupoki Samido, prop noisy methyl such as phenylene Rukarupokisamido) etc.
- Acryloxy preferably C 6 alkyl monopropoxy (eg, propanoyloxy, butanoyloxy, etc.)] and the like, each having 1 to 3 substituents, phenyl, 5 or 6-membered aromatic heterocyclic group or 5- to 8-membered monocyclic non-aromatic compound Ring group (preferably phenyl, pyridyl, Pi Perijiniru) may also be mentioned.
- halogen atoms C DOO 3 alkylenedioxy O carboxymethyl, Two Toro, Shiano, optionally halogenated C,.
- Alkyl optionally halogenated C,.
- Alkoxy which may have a substituent (; 6 _ 14 Ariru Okishi, which may have a substituent C 7 _ l9
- Ararukiruokishi which may have a substituent C 3 - 6 cycloalkyl
- alkylene group in the “optionally halogenated alkylene group represented by Y” include, for example, a C alkylene group [eg, _CH 2 —,-(CH 2 ) 2 _, _ (CH 2 ) 3 —, one (CH 2 ) 4 —, one (CH 2 ) 5 —, one (CH 2 ) 6 —, one CH (CH 3 ) one, one CH (C 2 ) —, One CH (CH (CH 3 ) 2 ) —, one C (CH 3 ) 2 —, one (CH (CH 3 )) 2 —, — (CH 2 ) 2 C (CH 3 ) 2 —,- (CH 2 ) 3 C (CH 3 ) 2- ].
- a C alkylene group [eg, _CH 2 —,-(CH 2 ) 2 _, _ (CH 2 ) 3 —, one (CH 2 ) 4 —, one (CH 2 ) 5 —, one (CH 2
- the alkylene group may be substituted with 1 to 5, preferably 1 to 3, halogen atoms (eg, fluorine, chlorine, bromine, iodine).
- halogen atoms eg, fluorine, chlorine, bromine, iodine.
- the halogen atom is preferably fluorine.
- the alkylene group is substituted with two or more halogen atoms, the types of the halogen atoms may be the same or different. '
- Y is preferably a C alkylene group, more preferably one CH 2 —, one CH (CH 3 ) —, one CH (C 2 H 5 ) _, one CH (CH (CH 3 ) 2 ) — and the like. It is.
- the ⁇ optionally halogenated C 6 alkyl '' represented by R is exemplified as the ⁇ substituent '' in the ⁇ cyclic group optionally having substituents '' represented by Ar 1 described above.
- substituents '' represented by Ar 1 those having 1 to 6 carbon atoms are used.
- optionally halogenated Cin those having 1 to 6 carbon atoms are used.
- 6 Alkyl is preferably C alkyl, especially methyl, ethyl, propyl, isopropyl and the like.
- Examples of the “substituent” in “phenyl which may have a substituent” and “pyridyl which may have a substituent” represented by R include, for example, a halogen atom (eg, fluorine, chlorine , Bromine, iodine, etc.), C ⁇ 3 alkylenedioxy (eg, methylenedioxy, ethylenedioxy, etc.), nitro, cyano, optionally halogenated C. Alkyl, optionally halogenated C 3-6 cycloalkyl, optionally halogenated C,. Alkoxy, optionally halogenated C; Alkylthio, hydroxy, amino, mono or di-C ⁇ -,.
- a halogen atom eg, fluorine, chlorine , Bromine, iodine, etc.
- C ⁇ 3 alkylenedioxy eg, methylenedioxy, ethylenedioxy, etc.
- nitro cyano
- Alkylamino eg, methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, acetylamino, dipropylamino, dibutylamino, ethylmethylamino, etc.
- formyl phoroxy, phorbamoyl, thiocarbamoyl, halogenated C ⁇ 6 alkyl monocarbonyl, C alkoxy-carbonyl (e.g.
- mono- or di-C 1 ⁇ alkyl-l-rubamoyl eg, nthylcarbamoyl, ethylcarbamoyl, dimethylcarbamoy
- R is preferably a hydrogen atom. '.
- Ra 1 Ra 2 Ra 3 and Ra 4 represented by “optionally halogenated alkyl”, “optionally halogenated ( 6 alkoxy)” and “optionally halogenated ( 6 alkylthio)” Is an optionally substituted halogenated C alkyl, which is exemplified as the “substituent” in the “optionally substituted cyclic group” represented by Ar 1 which may C _ 10 alkoxy "and” optionally halogenated good C,. of alkylthio "is used each one containing 1 to 6 carbon atoms.
- Ra 1, Ra 2 Ra 3 and Ra "halogenated _ 6 may be al Kill - Power Ruponiru” represented by 4 as the and "optionally halogenated (6 alkylsulfamoyl Honiru", the "substituted those exemplified as the definitive good C 7 _ 3_ 9 Ararukiru "have a group” substituent "is used, respectively.
- Halogen atoms represented by Ra 1 , Ra 2 Ra 3 and Ra 4 include, for example, fluorine, chlorine, bromine and iodine.
- Ra 1, Ra 2 Ra 3 and Ra 4 6 alkyl e.g., methyl, Echiru, propyl, isopropyl, heptyl
- Specific examples include methylamino, ethylamino, propylamino, isopropylamino, butylamino, dimethylamino, getylamino, dipropylamino, dibutylamino, and ethylmethylamino.
- Ra ′, Ra 2 , Ra 3 and Ra 4 are preferably the same or different and are a hydrogen atom or a C 6 alkyl which may be halogenated.
- Ra 1 , Ra 2 , Ra 3 and Ra 4 are more preferably a hydrogen atom.
- the “monocyclic aromatic ring” in the “optionally substituted monocyclic aromatic ring” represented by Ar includes benzene and a 5- or 6-membered aromatic heterocyclic ring.
- the “5- or 6-membered aromatic heterocycle” includes, for example, 5 or 6 containing, in addition to carbon atoms, one or more (for example, 1 to 3) heteroatoms selected from a nitrogen atom, a sulfur atom and an oxygen atom. And aromatic heterocycles.
- thiophene, furan, pyrrole, imidazole, pyrazol, thiazole, isothiazole, oxazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, oxaziazole, thiadiazole, furazane, etc. are listed.
- the “monocyclic aromatic ring” is preferably a benzene ring, a pyridine ring, a furan ring, a thiophene ring, and more preferably a benzene ring.
- the number of substituents is 1 to 4, preferably 1 or 2. When the number of substituents is two or more, each substituent may be the same or different.
- the substituent is preferably a halogen atom (preferably fluorine, chlorine, bromine, etc.), an optionally halogenated C, -IQ alkyl (preferably methyl, Ethyl, propyl, trifluoromethyl and the like), halogenated C ⁇ H) alkoxy (preferably methoxy, ethoxy and the like) C, which may be halogenated.
- Alkylthio preferably methylthio, etc.
- Jimechiruamino mono- or di-C alkylamino, formyl, force Rupokishi, C 6 an alkoxy - Karuponiru (preferably main Bok alkoxycarbonyl, Ethoxycarponyl, etc.), optionally halogenated C 6 alkyl-carboxamide (preferably methylcarboxamide, trifluoromethylcarboxamide, etc.), 5- to 6-membered non-aromatic heterocyclic group (preferably, pyrrolidinyl, etc.) And more preferably a halogen atom (preferably fluorine, chlorine, bromine, etc.), an optionally halogenated C ⁇ 6 alkyl (preferably methyl, ethyl, propyl, trifluoromethyl, etc.) which may be C bet 6 a Lucoxy (preferably, methoxy, ethoxy, etc.).
- C 6 an alkoxy - Karuponiru preferably main Bok alkoxycarbonyl, Ethoxycarpon
- Ar is preferably an unsubstituted benzene ring.
- R 1 and R 2 those exemplified as the aforementioned R 5 are used, and among them, methyl, ethyl, propyl and isopropyl are preferable.
- nitrogen-containing heterocycle in the “optionally substituted nitrogen-containing heterocycle” formed by R 1 and R 2 together with an adjacent nitrogen atom, the nitrogen in which R 3 and R 4 are adjacent What is illustrated as “nitrogen-containing heterocycle” in "nitrogen-containing heterocycle optionally having substituent (s)" formed together with atoms is used.
- azetidine, morpholine, thiomorpholine, piperidine, piperazine, pyrrolidine, hexamethyleneimine (azepan), 1,3-thiazolidine, m-imidazole, 45-dihydro-1H- ⁇ f Midazole, 2,3-dihydroindole, 1,2,3,4-tetrahydroquinoline, 1,2,34-tetrahydroisoquinoline and the like are preferred, as well as piperidine, piperazine, pyrrolidine, and Xamethyleneimine (azepan), morpholine, thiomorpholine and the like are preferred.
- piperidine, pyrrolidine, hexamethyleneimine, morpholine or thiomol Holin is preferred.
- substituted C 7 — 19 aralkyl and “substituent” exemplified as “substituent” in “optionally substituted cyclic group” represented by Ar 1 And an aromatic ring group optionally having:
- the number of substituents is, for example, 1 to 5, preferably 1 to 3. When the number of substituents is two or more, each substituent may be the same or different.
- the substituent is preferably C ⁇ , which may be halogenated.
- Alkyl (good Mashiku methyl, Echiru, propyl, butyl, isobutyl, etc.); halogenated also good c 3 _ 6 cycloalkyl (to preferably consequent opening hexyl, etc.); force Rubamoiru; mono- or di-C ⁇ 6 Alkyl monorubamoyl (preferably methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, methylcarbamoyl, etc.); 5- to 6-membered heterocyclic carbonyl (preferably morpholinocarbonyl, piperidinocarbonyl, 1_pyrrolidinylcarbonyl, etc.); halogen Optionally halogenated C 6 alkylsulfonyl (preferably methylsulfonyl and the like); optionally halogenated C alkyl-potassium lipoxamide (preferably acetoamide and the like); hydroxy-( ⁇ _ 6 alkyl (preferably
- substituents in the “optionally substituted C 7 ⁇ 9 aralkyl” and the “optionally substituted aromatic ring group” include a halogen atom (preferably, fluorine, chlorine and the like).
- a C ⁇ 6 alkyl which may be halogenated (preferably methyl, etc.), (preferably, methoxy, etc.) a C Bok 6 alkoxy optionally halogenated and the like are preferable.
- the number of substituents is, for example, 1 to 3, preferably 1 or 2. When the number of substituents is two or more, each substituent may be the same or different.
- the aforementioned "5- to 6-membered heterocyclic force Ruponiru" and “5- to 6-membered multiple ring power Lupo two root C DOO 6 alkyl” represents a halogen atom (preferably, fluorine, chlorine, etc.), halogenated And optionally has 1 to 3 substituents selected from C 6 alkyl (preferably, for example, methyl) and C 6 alkoxy (preferably, for example, methoxy) that may be halogenated. Is also good.
- the “substituent” in the “nitrogen-containing heterocyclic ring optionally having substituent (s)” is more preferably C 3, which may be halogenated.
- the “nitrogen-containing heterocyclic ring optionally having substituent (s)” formed by R 1 and Y together with an adjacent nitrogen atom includes the “substituted nitrogen atom formed by R 1 and R 2 together with an adjacent nitrogen atom”.
- substituent (s) formed by R 1 and Y together with an adjacent nitrogen atom.
- R 1 and R 2 are the same or different, a hydrogen atom or C, or shows a _ s alkyl, substituted with the nitrogen atom to which R 1 and R 2 are adjacent Compounds forming a nitrogen-containing heterocyclic ring which may be preferable, wherein R 1 and R 2 are Compounds that form a nitrogen-containing heterocyclic ring which may have a substituent together with an adjacent nitrogen atom are more preferred.
- Ar 1 is a group represented by the formula: Ar 3 _Ar 2 —
- Ar 2 is selected from a halogen atom (preferably, fluorine, chlorine, etc.) and optionally halogenated Ci- 6 alkyl (preferably, methyl, trifluoromethyl, X tyl, etc.) Phenyl, a 5- or 6-membered aromatic heterocyclic group, or a 5- to 8-membered monocyclic non-aromatic heterocyclic group (preferably phenyl, pyridyl, piberidinyl), each of which may have a substituent.
- a halogen atom preferably, fluorine, chlorine, etc.
- Ci- 6 alkyl preferably, methyl, trifluoromethyl, X tyl, etc.
- Phenyl a 5- or 6-membered aromatic heterocyclic group, or a 5- to 8-membered monocyclic non-aromatic heterocyclic group (preferably phenyl, pyridyl, piberidinyl), each of which may have a substituent.
- Ar 3 is a halogen atom (preferably, fluorine, chlorine, etc.), an optionally halogenated C alkyl (preferably, methyl, trifluoromethyl, ethyl, etc.), an optionally halogenated C, ⁇ 6 alkoxy (preferably, methoxy, trifluoromethoxy, etc.), optionally halogenated C 6 alkylthio (preferably, methylthio, etc.), C 6 ⁇ 3 alkylenedioxy (preferably, methylenedioxy, ethylenedioxy, etc.) optionally halogenated C 6 alkyl monoluponyl (preferably, acetyl, etc.) and octa-octenated C ⁇ 6 Alkyl-carboxamide (preferably, isopropyl ether lipoxamide and the like) may each have 1 to 3 substituents,
- Phenyl or a 5- or 6-membered aromatic heterocyclic group (preferably phenyl, pyridyl, etc.);
- Ra 1 , Ra 2 Ra 3 and Ra 4 may be the same or different and each may be a hydrogen atom or halogenated ( 6 alkyl;
- Oyobi 1 2 are the same or different, a hydrogen atom or a C ⁇ 6 alkyl (good Mashiku are methyl, Echiru, propyl, isopropyl);
- Y is ( ⁇ 6 alkylene group (preferably one CH 2 —, one CH (CH 3 ) —, —CH (C 2 H 5 ) one, one CH (CH (CH 3 ) 2 ) —);
- R is a hydrogen atom
- Ar is a halogen atom (preferably fluorine, chlorine, bromine and the like), an optionally halogenated C alkyl (preferably methyl, ethyl, propyl, trifluoromethyl and the like) and an optionally halogenated C ⁇ 6 Alkoxy (preferably methoxy, ethoxy, etc.)
- a compound that is a monocyclic aromatic ring preferably a benzene ring or a pyridin ring
- Ar 1 is a group represented by the formula: Ar 3 —Ar 2 _,
- Ar 2 is (preferably, fluorine, chlorine, etc.) a halogen atom and Bruno, halogenated are (preferably, methyl, triflusulfuron Ruo Russia methyl, X chill etc.)
- _ 6 alkyl may be one to three chosen from Phenyl, a 5- or 6-membered aromatic heterocyclic group, or a 5- to 8-membered monocyclic non-aromatic heterocyclic group (preferably phenyl, pyridyl, piberidinyl) which may have a substituent, and
- Ar 3 is a halogen atom (preferably, fluorine, chlorine, etc.), an optionally halogenated 6 alkyl (preferably, methyl, trifluoromethyl, ethyl, etc.), an optionally halogenated C 6 alkoxy ( preferably, methoxyethanol, etc. triflate Ruo b methoxy), good C 6 alkylene thioether which may be halogenated (preferably, methylthio, etc.), C ⁇ 3 alkylene O carboxymethyl (rather preferably is Mechirenjiokishi, etc.
- Echirenjiokishi Selected from the group consisting of optionally halogenated Ci 6 alkyl-carbonyl (preferably acetyl) and optionally halogenated C 6 alkyl-carbonyl (preferably isopropyl potassium). Each having 1 to 3 substituents,
- Phenyl or a 5- or 6-membered aromatic heterocyclic group (preferably phenyl, pyridyl, etc.);
- Ra 1 Ra 2 , Ra 3 and Ra 4 are the same or different and are each a hydrogen atom or halogenated Which may be _ 6 alkyl;
- C halogen which may be halogenated.
- alkyl preferably methyl, ethyl, propyl, butyl, isobutyl, etc.
- alkylated sulfonyl preferably methylsulfonyl, etc.
- a 3- to 8-membered nitrogen-containing heterocycle preferably piperidine, piperazine, pyrrolidine, hexamethyleneimine (azepane), morpholine, thiomorpholine
- Y is a C 6 alkylene group (preferably —CH 2 —, one CH (CH 3 ) —, one CH (C 2 H 5 ) one, —CH (CH (CH 3 ) 2 ) —);
- R is a hydrogen atom
- Ar is selected from a halogen atom (preferably, fluorine, chlorine, bromine, etc.) and optionally halogenated C ⁇ 6 alkyl (preferably, methyl, ethyl, propyl, cy (preferably, methoxy, ethoxy, etc.)
- a compound which is a monocyclic aromatic ring preferably a benzene ring or a pyridin ring
- Ar 1 is a halogen atom (e.g., fluorine, chlorine, bromine, iodine, etc.), - 3 ⁇ Rukirenjiokishi (eg, Mechirenjiokishi, etc. Echirenjiokishi), nitro, Shiano, C alkyl which may be halogenated, halogenated C may be. Alkoxy, which may have a substituent (preferably a halogen atom, optionally halogenated C, alkyl, optionally halogenated C, alkoxy, etc.) _ 14 aryloxy (preferably phenoxy) Shi), the substituent (preferably a halogen atom, a C ⁇ be halogenated -.
- a halogen atom e.g., fluorine, chlorine, bromine, iodine, etc.
- Rukirenjiokishi eg, Mechirenjiokishi, etc. Echirenjiokishi
- nitro Shiano
- C 7 _ 19 may have a Ararukiruokishi ( Preferably benzyloxy) and C which may have a substituent (preferably a halogen atom, optionally halogenated C, alkyl, optionally halogenated C, alkoxy, etc.) 3 -6 Cycloalkyl one C 6 alkoxy (preferably cyclopropylmethoxy and cyclo propyl ethoxy) Ashiru [preferably optionally halogenated optionally C ⁇ 6 alkyl Ichiriki Ruponiru (eg, Pentanoiru to, etc.
- halogenated C 6 alkylsulfonyl eg, butylsulfonyl, etc.
- acetyl-C 6 alkyl [preferably optionally halogenated C ⁇ 6 alkyl-potassium C ⁇ 6 alkyl (eg, Puropanoirumechi Le, prop noisy Rue chill, 2 - methylpropanoyl noisy methyl, Butanoirumechiru, have C DOO 6 alkyl sulfonyl optionally Lou C ⁇ 6 alkyl (e.g., propylsulfonyl Nirumechiru, butylsulfonyl methyl, etc.), C 6 - 1 4 ⁇ Li one Rukaruponiru one ( ⁇ _ 6 alkyl (for example, such as Benzoirumechiru) c 3 _ 6 cycloalkyl Ichiriki Lupo two Lou C ⁇ 6 alkyl (e.g., cyclo
- Phenyl a 5- or 6-membered aromatic heterocyclic group, or a 5- to 8-membered monocyclic non-aromatic heterocyclic group (preferably phenyl, pyridyl, piberidinyl);
- Ra Ra 2 , Ra 3 and Ra 4 are the same or different and each may be a hydrogen atom or a halogenated ( 6 alkyl;
- a C alkyl which may be halogenated (preferably methyl, Echiru, propyl, butyl, isobutyl, etc.) and optionally halogenated good c, (preferably methylsulfonyl, etc.) _ 6 alkylsulphonyl to 1 selected from A 3- to 8-membered nitrogen-containing heterocycle (preferably piperidine, piperazine, pyrrolidine, hexamethyleneimine (azepane), morpholine, thiomorpholine) which may have three substituents, respectively.
- a 3- to 8-membered nitrogen-containing heterocycle preferably piperidine, piperazine, pyrrolidine, hexamethyleneimine (azepane), morpholine, thiomorpholine
- Y is an alkylene group (preferably one CH 2 —, —CH (CH 3 ) —, —CH (C 2 H 5 ) one, —CH (CH (CH 3 ) 2 ) —);
- R is a hydrogen atom
- Ar is selected from a halogen atom (preferably fluorine, chlorine, bromine and the like), and an optionally halogenated C alkyl (preferably methyl, ethyl, propyl and cy (preferably methoxy, ethoxy and the like) 1
- a compound which is a monocyclic aromatic ring preferably a benzene ring or a pyridin ring
- Ar is selected from a halogen atom (preferably fluorine, chlorine, bromine and the like), and an optionally halogenated C alkyl (preferably methyl, ethyl, propyl and cy (preferably methoxy, ethoxy and the like) 1
- a compound which is a monocyclic aromatic ring preferably a benzene ring or a pyridin ring
- 3 to 3 substituents preferably a benzene ring or a pyridin ring
- Example 148 4- (2-cyclopropylethoxy) - ⁇ - (2- ⁇ 4- [1- (1-pyrrolidinyl) ethyl] phenyl ⁇ ethyl) benzamide (Example 148).
- compound (I) is a salt
- examples of such a salt include a salt with an inorganic base, an ammonium salt, a salt with an organic base, a salt with an inorganic acid, a salt with an organic acid, And salts with basic or acidic amino acids.
- Preferred examples of the salt with an inorganic base include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt, magnesium salt and barium salt; and aluminum salt.
- Preferred examples of the salt with an organic base include salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triene and the like. '
- salts with inorganic acids include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, and the like.
- salts with organic acids include formic acid, acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, maleic sulfonic acid, benzenesulfonic acid, P — Salts with toluenesulfonic acid and the like.
- Preferred examples of the salt with a basic amino acid include salts with arginine, lysine, ordinine and the like.
- salt with an acidic amino acid examples include salts with aspartic acid, glutamic acid, and the like.
- an alkali metal salt eg, a sodium salt, a potassium salt, etc.
- an alkaline earth metal salt eg, a calcium salt, a magnesium salt, a barium salt, etc.
- compound (I) when compound (I) has a basic functional group, it may be an inorganic salt such as a hydrochloride, a sulfate, a phosphate, or a perhydrohydrochloride;
- organic salts such as acetate, maleate, fumarate, succinate, methanesulfonate, P-toluenesulfonate, citrate and tartrate may be used.
- Compound (I) may be either an anhydride or a hydrate. In the case of a hydrate, it may have 0.5 to 3 water molecules
- Compound (I) is labeled with an isotope (eg, such as 3 H, 1 4 C, 3 5 S) It may be. .
- an isotope eg, such as 3 H, 1 4 C, 3 5 S
- compound (I) contains optical isomers, stereoisomers, positional isomers, and rotamers
- these compounds are also contained as compound (I), and are synthesized by known synthesis methods and separation methods. Each can be obtained as a single item.
- the compound (I) has an optical isomer
- the optical isomer separated from the compound is also included in the compound (I).
- the optical isomer can be produced by a method known per se. Specifically, an optical isomer is obtained by using an optically active synthetic intermediate or by optically resolving the final racemic mixture according to a conventional method.
- optical resolution method a method known per se, for example, a fractional recrystallization method, a chiral column method, a diastereomer method, and the like described in detail below are used.
- Racemic and optically active compounds eg, (+)-mandelic acid, (-) mono-mandelic acid, (+)-tartaric acid, (-) mono-tartaric acid, (+)-1-phenethylamine, (-)-1-)
- a method of forming a salt with phenethylamine, cinchonine, (-)-cinchonidine, brucine, etc. separating this by a fractional recrystallization method, and, if desired, obtaining a free optical isomer through a neutralization step.
- a method in which a racemate or a salt thereof is applied to an optical isomer separation column (chiral column) for separation For example, for liquid chromatography, add the mixture of optical isomers to a chiral column such as ENANTIO-0VM (manufactured by Tosoh Corporation) or Daicel CHIRAL series, and add water, various buffers (for example, phosphoric acid).
- a buffer solution) and an organic solvent eg, ethanol, methanol, isopropanol, acetonitrile, trifluoroacetic acid, getylamine, etc.
- separation is performed using a chiral column such as CP—Chirasil—DeXCB (manufactured by GL Sciences).
- Diastereomers of racemic mixtures by chemical reaction with optically active reagents The mixture is made into a single substance through ordinary separation means (for example, fractional recrystallization, chromatographic method, etc.), and then optically active reagent is obtained by chemical treatment such as hydrolysis reaction.
- a method of obtaining an optical isomer by separating a site For example, when the compound (I) has hydroxy or 1,2-amino in the molecule, the compound and an optically active organic acid (for example, MTPA [ ⁇ -methoxy- (trifluoromethyl) phenylacetic acid]), ) -Menthoxyacetic acid, etc.) to give a diastereomer of an ester form or an amide form, respectively.
- an optically active organic acid for example, MTPA [ ⁇ -methoxy- (trifluoromethyl) phenylacetic acid]
- a diastereomer of an amide or an ester can be obtained by subjecting the compound to an optically active amine or an alcohol reagent for a condensation reaction.
- the separated diastereomer is converted into an optical isomer of the original compound by subjecting it to an acid hydrolysis or a basic hydrolysis reaction.
- a prodrug of compound (I) is a compound that is converted into compound (I) by a reaction with an enzyme, gastric acid, or the like under physiological conditions in a living body, that is, a compound that is enzymatically oxidized, reduced, hydrolyzed, etc.
- the prodrug of compound (I) include compounds in which the amino group of compound (I) is acylated, alkylated, and phosphorylated [eg, the amino group of compound (I) is eicosanoylated, alanylated, and pentylaminocarbo.
- prodrug of compound (I) changes to compound 1 (I) under physiological conditions, as described in Hirokawa Shoten 1990, “Development of Drugs,” Volume 7, Molecular Design, pp. 163 to 198. It may be something.
- Compound (I) can be produced, for example, by the following [Production method 1] to [Production method 3] or a method analogous thereto.
- the compound used as the starting compound may be used as a salt.
- a salt those exemplified as the salt of the compound (I) described above are used.
- Compound (I) is produced, for example, by the following amidation reaction.
- the “amidation reaction” includes the following “method using a dehydrating condensing agent” and “method using a reactive derivative of carbonyl compound”.
- the compound ( ⁇ ), 1 to 5 equivalents of the compound (11), and 1 to 2 equivalents of the dehydrating condensing agent are reacted in an inert solvent. If necessary, the reaction may be carried out in the presence of 1 to 1.5 equivalents of 11-hydroxybenzotriazole ( ⁇ 0 ⁇ ) and / or a catalytic amount of 5 equivalents of a base. *
- dehydration condensing agent for example, dicyclohexylcarboimide (DCC), 1-ethyl-3- (3-dimethylaminopropyl) carboimide hydrochloride (WSC) and the like can be mentioned. WSC is particularly preferred.
- DCC dicyclohexylcarboimide
- WSC 1-ethyl-3- (3-dimethylaminopropyl) carboimide hydrochloride
- inert solvent examples include nitrile solvents (preferably acetonitrile), amide solvents (preferably DMF), halogenated hydrocarbon solvents (preferably dichloromethane), ether solvents (preferably dichloromethane). THF) and the like. These may be used as a mixture of two or more at an appropriate ratio.
- Alkali metal or alkaline earth metal hydrides eg, lithium hydride, sodium hydride, potassium hydride, calcium hydride, etc.
- alkali metal or alkaline earth metal amides eg, lithium amide, Na Strong bases such as razide, potassium hexamethyldisilazide, etc.
- lower alkoxides of alkali metals or alkaline earth metals eg, sodium methoxide, sodium ethoxide, potassium tert-butoxide
- alkali metal or alkaline earth metal hydroxides eg, sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, etc.
- alkali metal or alkaline earth metal carbonates eg, Inorganic bases such as sodium carbonate, potassium carbonate, cesium carbonate
- alkali metal 'or alkaline earth metal hydrogen carbonate eg, sodium hydrogen carbonate, potassium hydrogen carbonate, etc.
- Amines such as [5.4.0] indes-7-ene) and DBN (1,5 diazabicyclo [4.3.0] non-5-ene); for example, pyridine, imidazole, 2,6-lutidine And organic bases such as basic heterocyclic compounds.
- triethylamine, 4-dimethylaminopyridine and the like are preferable.
- the reaction temperature is usually room temperature (1 to 30 ° C, the same applies hereinafter).
- the reaction time is, for example, 10 to 24 hours.
- the reactive derivative of compound (II) is reacted with 1 to 5 equivalents (preferably 1 to 3 equivalents) of compound (III) in an inert solvent. If necessary, the reaction may be carried out in the presence of 1 to 10 equivalents, preferably 1 to 3 equivalents of a base.
- acid Puromido mixed acid anhydride (for example, C WINCH 6 alkyl Ichiriki carboxylic acid, C 6 - 1 0 ⁇ Acid anhydrides with cellulose carboxylic acid or C 6 alkyl carbonic acid, etc., active esters (eg, phenol optionally substituted, 1-hydroxybenzoic acid) Triazole or an ester with N-hydroxysuccinimide).
- mixed acid anhydride for example, C WINCH 6 alkyl Ichiriki carboxylic acid, C 6 - 1 0 ⁇ Acid anhydrides with cellulose carboxylic acid or C 6 alkyl carbonic acid, etc.
- active esters eg, phenol optionally substituted, 1-hydroxybenzoic acid
- Triazole or an ester with N-hydroxysuccinimide Triazole or an ester with N-hydroxysuccinimide
- Examples of the “substituent” in the “optionally substituted phenol” include a halogen atom (eg, fluorine, chlorine, bromine, iodine, etc.), nitro, optionally alkylated C alkyl, And optionally halogenated C- 6 alkoxy.
- the number of substituents is, for example, 1 to 5.
- the "optionally C ⁇ 6 alkyl which may be halogenated”, as the “optionally halogenated C [Bok 6 alkoxy”, those exemplified as the Ra 1 is their respective use.
- phenol which may have a substituent include, for example, phenol, pentachlorophenol, penfluorophenol, p-nitrophenol and the like.
- the reactive derivative is preferably an acid halide.
- inert solvent examples include ether solvents, halogenated hydrocarbon solvents, aromatic solvents, nitrile solvents, amide solvents, ketone solvents, sulfoxide solvents, and water. . These may be used as a mixture of two or more at an appropriate ratio. Above all, preferred are acetonitrile, THF, dichloromethane, chloroform and the like.
- the base is preferably sodium hydride, carbonated carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium hydrogencarbonate, potassium hydrogencarbonate, triethylamine, pyridine and the like.
- the reaction temperature is usually from 20 ° C. to 50 ° (:, preferably room temperature.
- the reaction time is usually from 5 minutes to 40 hours, preferably from 1 to 18 hours.
- the compound (III) can be produced by a method known per se, for example, the method described in W001 / 82925 or a method analogous thereto.
- the compound (II) can be produced by a method known per se.
- Ar 1a represents a non-aromatic cyclic amino group which may have a substituent, and other symbols have the same meanings as described above.
- specific examples of the non-aromatic cyclic amino group include pyrrolidinyl, piberidinyl, piperazinyl, morpholinyl, and thiomorpholinyl.
- This reaction is carried out by reacting compound (Ib) with 1 to 5 equivalents (preferably 1 to 1.5 equivalents) of compound (IV) in an inert solvent in the presence of a base.
- the base is preferably potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, sodium bicarbonate, sodium bicarbonate, triethylamine, pyridine and the like.
- the amount of the base to be used is, for example, 1 to 10 equivalents, preferably 1 to 3 equivalents, relative to the compound (lb).
- inert solvent examples include alcohol solvents, ether solvents, halogenated hydrocarbon solvents, aromatic solvents, nitrile solvents, amide solvents, ketone solvents, sulfoxide solvents, and water. No. These are two types The above may be mixed and used at an appropriate ratio. Among them, preferred are acetonitrile, DMF, acetone, ethanol, pyridine and the like.
- the reaction temperature is usually about 120 ° C. to 100 ° C., preferably room temperature to 80 ° C.
- the reaction time is, for example, about 0.5 hours to 1 day.
- Compound (IV) described above can be produced by a method known per se.
- Compound (lb) can be produced, for example, according to the above-mentioned [Production method 1].
- Ar 1 is represented by the formula: Ar 3 — Ar 2a — (wherein, Ar 2a is an aromatic group which may have a substituent, and Ar 3 has the same meaning as described above)
- the group compound (Id) can also be produced, for example, by the following aryl coupling reaction.
- L 1 represents hydroxy or C ⁇ 6 alkoxy
- L 2 represents a halogen atom or trifluoromethanesulfonyloxy; other symbols are as defined above.
- the C ⁇ 6 alkoxy represented by L 1 for example methoxy, ethoxy, flop Robokishi, butoxy, Penchiruokishi, etc. Kishiruokishi the like to.
- halogen atom represented by L 2 for example, fluorine, chlorine, bromine, and the like iodine. Of these, chlorine and bromine are preferred.
- a cyclic group is an aromatic group That are:
- Ar 3 and Ar 2a are both phenyl which may have a substituent
- Ar 3 _Ar 2a — is biphenyl which may have a substituent. Certain cases are preferred.
- the aryl coupling reaction is carried out by a method known per se, for example, the method described in Acta. Chemica Scandinavia, pp. 212-1230, 1993, or the like. It can be done according to the method.
- the compound (I c) is reacted with 1 to 3 equivalents (preferably 1 to 1.5 equivalents) of the compound (V) in an inert solvent in the presence of a base and a transition metal catalyst. It is performed by.
- the base is preferably sodium carbonate, sodium hydrogen carbonate and the like.
- the amount of the “base” to be used is, for example, usually about 1 to 10 equivalents relative to compound (I c).
- Examples of the “transition metal catalyst” include a palladium catalyst and a nickel catalyst.
- Examples of the “palladium catalyst” include tetrakis (triphenylphosphine) palladium (0), palladium acetate, bis (triphenylphosphine) palladium (II) chloride, and palladium monocarbon.
- Examples of the “nickel catalyst” include tetrakis (triphenylphosphine) nickel (0).
- the amount of the “transition metal catalyst” to be used is generally about 0.01 to 1 equivalent, preferably about 0.01 to 0.5 equivalent, relative to compound (Ic).
- the reaction temperature is usually from room temperature to 150 ° C., preferably about 80 to 150.
- the reaction time is, for example, about 1 to 48 hours.
- inert solvent examples include water, alcohol solvents, and aromatic solvents. Medium and the like. These may be used as a mixture of two or more at an appropriate ratio. Among them, water, ethanol, toluene and the like alone or a mixed solvent of two or more thereof are preferable.
- Compound (V) described above can be produced by a method known per se.
- Compound (I C) can be produced, for example, according to the above-mentioned [Production method 1].
- the “alcohol-based solvent” include methanol, ethanol, isopropazole, and tert-butanol.
- ether-based solvent examples include getyl ether, tetrahydrofuran (THF;), 1,4-dioxane, 1,2-dimethoxyethane, and the like.
- halogenated hydrocarbon solvent for example, dichloromethane, chloroform, 1,2-dichloroethane, carbon tetrachloride and the like are used.
- aromatic solvent for example, benzene, toluene, xylene, pyridine and the like are used.
- hydrocarbon solvent for example, hexane, pentane, cyclohexane and the like are used.
- amide solvent for example, N, N-dimethylformamide (DMF), ⁇ , ⁇ -dimethylacetamide, ⁇ -methylpyrrolidone and the like are used.
- ketone-based solvent for example, acetone, methylethyl ketone and the like are used.
- sulfoxide solvent for example, dimethyl sulfoxide (DMS0) and the like are used.
- nitrile solvent for example, acetonitrile, propionitrile and the like are used.
- the functional group in the molecule can be converted to the target functional group by combining chemical reactions known per se.
- chemical reactions include oxidation, reduction, alkylation, and hydrolysis. Reaction, amination reaction, esterification reaction, aryl coupling reaction, deprotection reaction and the like.
- a protecting group generally used in peptide chemistry or the like is introduced into these groups.
- the target compound can be obtained by removing the protecting group as necessary after the reaction.
- Examples of the protecting group for an amino group include formyl, C 6 alkyl monopropyl (eg, acetyl, propionyl, etc.), and C 6 alkoxy monopropyl (eg, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.) ), Benzoiru, C 7 one 10 Ararukiru Ichiriki Ruponiru (e.g., benzyl Cal Poni Le),
- These groups may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine, etc.), ( ⁇ _ 6 alkoxy (e.g., methoxy, ethoxy, propoxy, etc.) or the like in substituted nitro Is also good.
- halogen atoms e.g., fluorine, chlorine, bromine, iodine, etc.
- ⁇ _ 6 alkoxy e.g., methoxy, ethoxy, propoxy, etc.
- Examples of the protecting group for a carboxy group include, for example, 6 alkyl (eg, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.), C 7 -aralkyl (eg, benzyl, etc.), phenyl, trityl, silyl ( examples, trimethylsilyl, Toryechirushiriru, dimethyl phenylalanine silyl, tert- heptyl dimethyl silyl, tert- Petit Rougier chill silyl, etc.), C 2 _ 6 alkenyl (e.g., 1-Ariru) and the like.
- 6 alkyl eg, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.
- C 7 -aralkyl eg, benzyl, etc.
- These groups may be substituted with one to three halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), alkoxy (eg, methoxy, ethoxy, propoxy, etc.) or nitro.
- halogen atoms eg, fluorine, chlorine, bromine, iodine, etc.
- alkoxy eg, methoxy, ethoxy, propoxy, etc.
- ( ⁇ _ 6 alkyl e.g., methyl, E chill, propyl, isopropyl, butyl, tert- butyl, etc.
- phenyl e.g., benzyl, etc.
- C 7 _ 10 Ararukiru e.g., benzyl, etc.
- These groups may be substituted by 1 to 3 halogen atoms (e.g., fluorine, chlorine, bromine, iodine), ( ⁇ _ 6 alkyl (e.g., methyl, Echiru, n- propyl, etc.), C x _ 6 alkoxy (e.g. , Methoxy, ethoxy, propoxy, etc.) or nitro.
- halogen atoms e.g., fluorine, chlorine, bromine, iodine
- ⁇ _ 6 alkyl e.g., methyl, Echiru, n- propyl, etc.
- C x _ 6 alkoxy e.g. , Methoxy, ethoxy, propoxy, etc.
- Examples of the carbonyl-protecting group include cyclic acetal (eg, 1,3-dioxane, etc.) and acyclic acetal (eg, di-C ⁇ 6 alkyl acetal, etc.). .
- the above-mentioned method for removing the protecting group can be carried out according to a method known per se, for example, the method described in Protective Groups in Organic Synthes is, published by John Wiley and Sons (1980). It can be carried out.
- acids, bases, ultraviolet light, hydrazine, phenylhydrazine, sodium N-methyldithiolrubamate, tetrabutylammonium fluoride, palladium acetate, trialkylsilyl halides (eg, trimethylsilyl halide, trimethylsilyl bromide, etc.) , The reduction method, etc. are used.
- Compound (I) can be isolated and purified by known means, for example, solvent extraction, liquid conversion, phase transfer, crystallization, recrystallization, chromatography and the like.
- the starting compound of compound (I) or a salt thereof can be isolated and purified by the same known means as described above, but is directly used as a starting material in the next step as a reaction mixture without isolation. May be.
- Compound (I) and its prodrug (hereinafter sometimes abbreviated as the compound of the present invention) have excellent MCH receptor antagonistic activity and are therefore useful as preventive and therapeutic agents for diseases caused by MCH.
- the compounds of the present invention are toxic (eg, acute Toxicity, chronic toxicity, genotoxicity, reproductive toxicity, cardiotoxicity, drug interaction, carcinogenicity) are low, and it is excellent in oral absorption and in the brain.
- the compound of the present invention can be used for preventing and treating diseases caused by MCH in mammals (for example, lads, mice, guinea pigs, egrets, higgins, magpies, bushfishes, magpies, monkeys, humans, etc.). It is safely administered as an agent.
- mammals for example, lads, mice, guinea pigs, egrets, higgins, magpies, bushfishes, magpies, monkeys, humans, etc.
- the diseases caused by MCH include, for example, obesity [eg, malignant mastocytosis, exogenous obesity (hyperinsulinar obesity), hyperplasmic obesity (1 ⁇ 6 1 & 311 ⁇ obesity), hypophyseal adiposity, hypoplasmic obesity
- obesity eg, malignant mastocytosis, exogenous obesity (hyperinsulinar obesity), hyperplasmic obesity (1 ⁇ 6 1 & 311 ⁇ obesity), hypophyseal adiposity, hypoplasmic obesity
- hypoplasmic obesity ⁇ hypothyroid obesity, hypothalamic obesity, symptomatic obesity, childhood obesity (infantile obesity), upper body obesity, Dietary obesity (alimentary obesity), hypogonadal obesity, systemic mastocytosis, simple obesity, central obesity, etc.], increased eating Disorders (hype ⁇ hagia), affective disorders, sexual dysfunction, depression, anxiety.
- the compound of the present invention is also useful as a preventive / therapeutic agent for lifestyle-related diseases such as diabetes, diabetic complications (eg, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, etc.), arteriosclerosis, and knee arthritis. It is.
- lifestyle-related diseases such as diabetes, diabetic complications (eg, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, etc.), arteriosclerosis, and knee arthritis. It is.
- the compound of the present invention is also useful as an antifeedant.
- the compound of the present invention can also be used in combination with diet therapy (eg, diet therapy for diabetes, etc.) and exercise therapy.
- diet therapy eg, diet therapy for diabetes, etc.
- exercise therapy e.g, exercise therapy for exercise.
- the compound of the present invention can be used for prevention or treatment of dyschromia due to melanin or melanocyte abnormality.
- the pigmentary disorders include pigment enhancement and pigment reduction.
- Pigment enhancement includes drug pigmentation caused by anticancer drugs, etc .; diseases such as endocrine and metabolic disorders (eg, Addison's disease), genetic disorders, chronic liver disorders, renal failure, black epidermis, and systemic sclerosis Pigmentation and achromatism associated with the disease.
- Pigment reduction includes phenylketonuria, systemic or localized albinism, and foliate white with tuberous sclerosis Plaques or spotted vitiligo; depigmentation associated with systemic sclerosis.
- the compounds of the present invention can also be used for the prevention or treatment of pigmentation disorders due to spots, freckles, sunburn and the like; and also for pigment enhancement or pigment attenuation for cosmetic purposes.
- the medicament of the present invention is produced by formulating the compound of the present invention as it is or together with a pharmacologically acceptable carrier by a means known per se.
- the pharmacologically acceptable carrier includes various organic or inorganic carrier substances commonly used as pharmaceutical materials, such as excipients, lubricants, binders, disintegrants in solid preparations, and solvents in liquid preparations. And solubilizing agents, suspending agents, isotonic agents, buffers, soothing agents and the like.
- additives such as preservatives, antioxidants, coloring agents, sweeteners, adsorbents, and wetting agents can be used as necessary.
- Excipients include, for example, lactose, sucrose, D-mannitol, starch, corn starch, crystalline cellulose, light caffeic anhydride and the like.
- lubricant examples include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
- binder examples include crystalline cellulose, sucrose, D-mannitol, dextrin, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, starch, sucrose, gelatin, methylcellulose, and sodium propyloxymethylcellulose.
- Disintegrators include, for example, starch, carboxymethylcellulose, calcoxymethylcellulose calcium, croscarmellose sodium, carboxymethylstarnadium, low-substituted hydroxypropylcellulose (L-HPC), and the like.
- solvent examples include water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil and the like.
- Solubilizing agents include, for example, polyethylene glycol, propylene glycol, D-mannyl, benzyl benzoate, ethanol, and trisaminomethyl. Tan, cholesterol, triethanolamine, sodium carbonate, sodium citrate and the like.
- suspending agents include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalcodium chloride, benzethonium chloride, and glyceryl monostearate; for example, polyvinyl alcohol,
- surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalcodium chloride, benzethonium chloride, and glyceryl monostearate
- polyvinyl alcohol examples include hydrophilic polymers such as polyvinylpyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose.
- tonicity agent examples include glucose, D-sorbitol, sodium chloride, glycerin, D-mannitol and the like.
- buffers such as phosphate, acetate, carbonate, and citrate.
- Examples of the soothing agent include benzyl alcohol and the like.
- preservative examples include paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidant examples include sulfite, ascorbic acid and the like.
- dosage form of the medicament of the present invention examples include tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, and orally disintegrating tablets), powders, granules, capsules (including soft capsules), and liquids.
- Oral preparations eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.), external preparations (eg, nasal administration preparations, transdermal preparations, ointments, etc.), Parenteral such as suppositories (eg, rectal suppositories, vaginal suppositories, etc.), sustained release agents (eg, sustained release micro-oral capsules, etc.), pellets, drops, pulmonary agents (inhalants), eye drops, etc. Agents and the like. These formulations can be safely administered orally or parenterally (eg, topically, rectally, intravenously, etc.).
- parenterally eg, topically, rectally, intravenously, etc.
- the content of the compound of the present invention in the medicament of the present invention is, for example, about 0.1 to 100% by weight of the whole medicament.
- the dose of the compound of the present invention is appropriately selected depending on the administration subject, administration route, disease and the like.
- the daily dose is about 0.1 to about 500 mg, preferably about 1 to about 100 mg, more preferably about 5 to about 100 mg. Approximately 100 mg, which can be administered once or several times a day.
- the compound of the present invention is, for example, for the purpose of ⁇ enhancing the therapeutic effect of the compound of the present invention on obesity '', ⁇ enhancing the therapeutic effect of the compound of the present invention on depression or anxiety '', ⁇ reducing the amount of the compound of the present invention '', and the like. It can be used in combination with a concomitant drug that does not adversely affect the compound of the present invention.
- concomitant drugs examples include, for example, “diabetic drugs”, “diabetic complication drugs”, “anti-obesity drugs other than MCH antagonists”, “hypertensive drugs”, “hyperlipidemic drugs” (Therapeutic agents for arteriosclerosis), “therapeutic agents for arthritis”, “anxiolytics”, “antidepressants” and the like. Two or more of these concomitant drugs may be used in combination at an appropriate ratio.
- agents for treating diabetes include insulin sensitizers, insulin secretagogues, biguanides, insulin, mono-dalcosidase inhibitors, and 33] adrenergic receptor agonists.
- H-surin resistance ameliorating agent examples include pioglitazone or a salt thereof (preferably hydrochloride), torodarisuzone, oral siglisuzone or a salt thereof (preferably maleate), reglixane (J TT-501), GI-262570, Netoglitazone (MCC-555), YM-440, DRF-2593, BM-13-13258, KRP_297, R-19702, CS-01K FK-61, WO99 / 58510 (for example, (E) -4- [4- (5-methyl-2-phenyl-4-oxazolylmethoxy) benzyloxyimino] -4-phenylbutyric acid), Tesaglitazar (Tesaglitazar) AZ-242), Ragaglitazar (No.-622), BMS-298585, ONO-5816, BM-13-13258, LM-4156, MBX-102, LY-519818, MX-6054,
- insulin secretagogues examples include sulfonylurea agents.
- Specific examples of the sulfonylurea agent include tolpumidamide, chlorpropamide, tolazamide, acetohexamide, daliclopyramide and its ammonium salt, dalibenclamide, daliclazide, glimepiride and the like.
- insulin secretagogues examples include levaglinide, nateglinide, mitiglinide (KAD-1229), JTT-608, and the like.
- biguanides examples include metformin, buformin, phenformin and salts thereof (eg, hydrochloride, fumarate, succinate).
- insulin for example, animal insulin extracted from the stomach of pigs and bush; semi-synthetic human insulin that is enzymatically synthesized from insulin extracted from porcine ginseng; genetic engineering using Escherichia coli and yeast And human insulin synthesized as described above.
- insulin insulin zinc containing 0.45 to 0.9 (wZw)% of zinc; zinc chloride, prominin insulin produced from prominin sulfate and insulin, and the like are also used. Further, insulin may be a fragment or derivative thereof (eg, INS-1, etc.).
- Insulin includes various types such as ultra-rapid-acting, rapid-acting, biphasic, intermediate, and sustained-acting insulins, which can be appropriately selected depending on the patient's condition.
- dalcosidase inhibitor examples include acarpose, poglipois, miglitol, and emidalitate.
- Adrenergic receptor agonists include, for example, A J-9677, BMS-196085, SB-226552, AZ40140, CP-331684, and the like.
- examples of the "agent for treating diabetes” include ergoset, pramlinide, leptin, BAY-27-9955 and the like.
- Examples of the "drug for treating diabetic complications” include, for example, aldose reductase inhibitors, Dallation inhibitors, protein kinase C inhibitors and the like.
- aldose reductase inhibitors include i!), Such as tolrestat; epalrestat; imirestat; zenarestat; fidarestat (SNK-860); zovolrestat; ARI_509; AS-3201. '
- Glycation inhibitors include, for example, pimagedine and the like.
- protein kinase C inhibitors include NGF, LY-333531 and the like.
- “Drugs for treating diabetic complications” include, for example, alprosil, tiapride hydrochloride, cilostazol, mexiletine hydrochloride, ethyl ethyl icosabento, memantine, pimagedline (ALT-711), neurotrophic factor And its increasing drugs (eg, NGF, NT-3, BDNF, neurotrophin production and secretagogues described in W001 / 14372) (eg, 4- (4-chlorophenyl) -2_ (2-methyl-1 -Imidazolyl) -5- [3- (2-methylphenoxy) propyl] oxazole and the like), nerve regeneration promoters (eg, Y-128, etc.) and the like.
- anti-obesity drug other than the MCH antagonist examples include a ribose inhibitor, an appetite suppressant, and an i83 adrenergic receptor agonist.
- lipase inhibitor examples include orlistat, ATL-962, and the like.
- Appetite suppressants include, for example, mazindol, dexfenfuramine, fluoxetine, sibutramine, and viamin.
- Examples of the / 33 adrenergic receptor agonist include the “/ 33 adrenergic receptor agonist” exemplified as the “diabetic agent” above.
- anti-obesity drugs other than MCH antagonists include, for example, ribstatin and the like.
- agents for treating hypertension include angiotensin converting enzyme inhibitors, calcium antagonists, potassium channel openers, angiotensin II antagonists and the like.
- Angiotensin converting enzyme inhibitors include, for example, captopril, genara Prill, arasepril, delapril (hydrochloride), lisinopril, imidabril, benazepril, cilazapril, temocapril, trandolapril, and manidipine (hydrochloride).
- Examples of the calcium antagonist include difludipine, amlodipine, eforidipine, dicardipine and the like.
- Potassium channel openers include, for example, Levcromakalim, L-27152,
- angiotensin II antagonists include oral sultan, candesartan cilexicil, valsartan, irbesartan, CS_866, and ⁇ 4-7. '
- hypolipidemic agent therapeutic agent for arteriosclerosis
- fibrate compounds examples include HMG-CoA reductase inhibitors, fibrate compounds and the like.
- HM G—Co A reductase inhibitors include, for example, pravastin, simpastin, oral baths, atorvastatin, fullbasstin, ripanchil, ceribas, itabass, and rossbasin (ZD4 52 2) or their salts (eg, sodium salt, calcium salt, etc.).
- the fibrate-based compound include bezafibrate, clinofibrate, clofibrate, and simfibrate.
- agents for treating arthritis include, for example, ibuprofen.
- agents for treating arthritis include, for example, ibuprofen.
- anxiolytics include chlordiazepoxide, diazepam, oxazolam, medazepam, cloxazolam, bromazepam, lorazepam, albrazolam, fludiazepam and the like.
- anti-depressant examples include fluoxetine, flupoxamine, imibramine, paroxetine, and sertraline.
- the administration time of the above-mentioned concomitant drug is not limited, and the compound of the present invention and the concomitant drug may be administered to a subject to be administered simultaneously or at an interval.
- the dose of the concomitant drug may be in accordance with the clinically used dose and can be appropriately selected depending on the administration subject, administration route, disease, combination, and the like. ⁇ You can. '
- the administration form of the concomitant drug is not particularly limited as long as the compound of the present invention and the concomitant drug are combined at the time of administration.
- Such administration forms include, for example, 1) administration of a single preparation obtained by simultaneously formulating the compound of the present invention and the concomitant drug, and 2) separate preparation of the compound of the present invention and the concomitant drug. 3) Administration of the two preparations obtained by separately formulating the compound of the present invention and the concomitant drug at different times by the same administration route.
- the compounding ratio of the compound of the present invention and the concomitant drug can be appropriately selected depending on the administration subject, administration route, disease and the like.
- a partial structural formula: -C0-N (R) -C (Ra ') (Ra 2 ) -C (Ra 3 ) (Ra 4 )-[wherein the symbols have the same meanings as described above. ] group represented by is, - CH 2 - NH- C0- C3 ⁇ 4 -,, -NH-CO-CH 2 -CH 2 -, -NH-C0-CH CH-, -CH r CH 2 -NH-C0 -, - NH- CO- CH 2 - 0_,
- the compound may be abbreviated as “Group A” below) because it has MCH receptor antagonistic activity, and thus can be used as a prophylactic or therapeutic agent for MCH-induced diseases in mammals in the same manner as the compound of the present invention. it can.
- Compound group A can be produced in the same manner as compound (I).
- Compound group A can be formulated in the same manner as the compound of the present invention, and can also be used in combination with a concomitant drug.
- the present invention is further described in detail by the following Reference Examples, Examples, Formulation Examples, and Experimental Examples, which do not limit the present invention, and may be changed without departing from the scope of the present invention. Good.
- room temperature indicates 1 to 30, and anhydrous magnesium sulfate or anhydrous sodium sulfate was used for drying the organic layer.
- % Means percent by weight unless otherwise specified.
- the infrared absorption spectrum was measured by a diffuse reflection method using a Fourier transform infrared spectrophotometer.
- FABMS (pos) is the mass spectrum measured by the (+) method in Fast Atom Bombardment Mass Spectrometry.
- WSCD 1-Ethyl-3- (3-dimethylaminopropyl) carbodiimide.
- HOB t 1-hydroxy-1H_benzotriazole
- Lithium aluminum hydride was added to a solution of methyl 4- ⁇ 2-[(tert-butoxycarbonyl) amino] ethyl ⁇ benzoate (550 mg, 1.97 mL) obtained in Reference Example 2 in tetrahydrofuran (10 ml) at 0 ° C. Was added and stirred at room temperature for 1 hour.
- Ethyl acetate was added to the reaction solution, washed with 0.5 N hydrochloric acid and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The obtained residue was purified by alumina column chromatography (developing solvent: ethyl acetate) to obtain a colorless oil.
- Trifluoroacetic acid (9 ml) was added to tert-butyl 2- [4- (topyrrolidinylmethyl) phenyl] ethylcarbamate (526 mg, 1.73 bandol) obtained in Reference Example 3, and the mixture was stirred for 2 hours. It was concentrated under reduced pressure. Ethyl acetate was added to the residue, and the mixture was washed with a saturated aqueous solution of potassium carbonate and brine, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain the title compound (239 mg).
- Ethyl 4-acetyl benzoate (5.00 g, 26.0 mmol) was added to a tetrahydrofuran solution (130 ml) of ethyl acetyl ethyl acetylphosphonoacetate (6.71 ml, 33.8 band 1) and potassium tert-butoxy (4.38 g, 39.0 mmol) at 0 ° C. The mixture was stirred at room temperature for 16 hours. Ethyl acetate was added to the reaction solution, washed with saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained residue was purified by NH-silica gel column chromatography (developing solvent: ethyl acetate).
- developer solvent ethyl acetate
- the obtained oil and a solution of 10% palladium carbon (lg) in ethanol (150 ml) were stirred under a hydrogen atmosphere for 2 hours, and filtered through celite.
- the solvent was distilled off under reduced pressure, and the obtained residue was purified by NH-silica gel column chromatography (eluent: ethyl acetate) to give the title compound (5.67 g).
- the title compound was obtained by the same procedures as in Reference Example 19 using 4-bromo-N- (2-phenylethyl) benzamide and Shiojiri 4-butyril.
- Example 2 The same procedure as in Example 2 was carried out using 4-promorediline and [4- (hydroxymethyl) phenoxy] acetic acid to give the title compound.
- Triethyl phosphite (8.58 ml, 50 mmol) was added to ethyl bromo (phenyl) acetate (9.73 g, 40.0 mniol), and the mixture was stirred at 160 ° C for 1 hour, and then triethyl phosphite (8.58 ml, 50 mmol). ) was added and stirred for 1 hour. After the excess triethyl phosphite was distilled off under reduced pressure, the residue was dissolved in tetrahydrofuran (100 ml). This solution was added dropwise at 0 ° C.
- Example 6 As in Example 6, using ⁇ - (4-bromophenyl) -2- 2- [4- (2-oxopropyl) phenoxy] propanamide obtained in Reference Example 36 and 4_chlorophenylphenolic acid. By performing the above operation, the title compound was obtained.
- Example 6 The same operation as in Example 6 was performed using ⁇ - (4-bromobenzyl) -2- [4- (topyrrolidinylmethyl) phenyl] acetoamide obtained in Reference Example 38 and 4-chlorobutenylporonic acid. To give the title compound.
- Example 6 The same operation as in Example 6 was performed using ⁇ - (4-bromophenyl) -3- [4- (1-pyrrolidinylmethyl) phenyl] propanamide obtained in Reference Example 41. The title compound was obtained.
- Example 3 The same operation as in Example 2 was performed using ( ⁇ ) -2-phenyl-3- [4- (topyrrolidinylmethyl) phenyl] -2-propenoic acid hydrochloride obtained in Reference Example 31. This gave the title compound.
- Example 6 was repeated using ( ⁇ ) _ ⁇ - (4-bromophenyl) -2-phenyl-3- [4- (1-pyrrolidinylmethyl) phenyl] -2-propenamide obtained in Reference Example 48.
- the title compound was obtained by the same operation.
- Example 50 Using N- (4-bromo-2-fluorophenyl) -3- [4- (topyrrolidinylmethyl) phenyl] propanamide obtained in Example 50, the same operation as in Example 6 was performed to obtain The title compound was obtained.
- Example 52 The same operation as in Example 6 was performed using ⁇ - (4-bromo-2-fluorophenyl) -2- [4- (1-pyrrolidinylmethyl) phenoxy] acetoamide obtained in Example 52. The title compound was obtained.
- Example 33 The same procedure as in Example 2 was carried out using ( ⁇ ) -3- (4-chlorophenyl) -3- (4- (topyrrolidinylmethyl) phenyl) -2-propenoic acid hydrochloride obtained in Reference Example 33. By performing the operation, the title compound was obtained.
- Example 6 The same operation as in Example 6 was performed using 3- (4-bromophenyl) -N- [4-G-pyrrolidinylmethyl) phenyl] propanamide obtained in Reference Example 56 to obtain the title compound The compound was obtained.
- Example 6 was carried out using ( ⁇ ) -3- (4-bromophenyl; nyl) -N- [4- (1-pyrrolidinylmethyl) phenyl] -2-propenamide obtained in Reference Example 58 ′.
- the title compound was obtained by performing the same operation.
- the title compound was obtained by performing the same operation as in Reference Example 43 using N- (4-bromophenyl) -2- (4-formylphenoxy) propanamide obtained in Reference Example 35 and pyrrolidine. .
- Example 5 The same operation as in Example 6 was performed using ⁇ - (4-bromophenyl) -2- [4- ⁇ -pyrrolidinylmethyl) phenoxy] propanamide obtained in Reference Example 62. The title compound was obtained.
- Tri- (4-hydroxyphenyl) ethanone (1.81g, 13.3 bandits 01), 2-bromo-N- (4-bromophenyl) acetamide (3.00g, 10.2 bands 01) and potassium carbonate (4.25g, 30.7 recitation 01)
- DMF 20 ml
- the reaction solution was diluted with ethyl acetate, washed with saturated saline, and dried over anhydrous sodium sulfate.
- Example 10 The same procedure as in Example 10 was performed using N- [4- (4-chlorobutanoyl) benzyl] acetamide and 4- (4-chlorophenyl) piperidine to obtain the title compound.
- the extract was washed with saturated saline and dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure.
- the reaction solution was concentrated under reduced pressure, ethyl acetate was added to the residue, washed with a saturated aqueous solution of potassium hydrogen carbonate and saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
- the obtained residue was purified by NH-silica gel column chromatography (eluent: ethyl acetate), and triturated with hexane to give the title compound (278 mg).
- the obtained residue was purified by alumina column chromatography (developing solvent; ethyl acetate). To the obtained oil is added 4N hydrogen chloride-ethyl acetate and triturated with isopropyl ether to give the title compound.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/545,120 US7601868B2 (en) | 2003-02-12 | 2004-02-12 | Amine derivative |
EP04710515A EP1593667A4 (en) | 2003-02-12 | 2004-02-12 | AMINE DERIVATIVE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003034010 | 2003-02-12 | ||
JP2003-034010 | 2003-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004072018A1 true WO2004072018A1 (ja) | 2004-08-26 |
Family
ID=32866256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/001467 WO2004072018A1 (ja) | 2003-02-12 | 2004-02-12 | アミン誘導体 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7601868B2 (ja) |
EP (1) | EP1593667A4 (ja) |
WO (1) | WO2004072018A1 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063239A1 (de) * | 2003-12-23 | 2005-07-14 | Boehringer Ingelheim International Gmbh | 3-(4-piperidin-1ylmethyl-phenyl) -propionsäure-phrnylamid-derivate und verwandte verbindungen als mch (melanine concentrating hormone) antagonisten zur behandlung von essstörungen |
WO2006118320A1 (ja) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | チエノピリミドン化合物 |
WO2008001778A1 (fr) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Animal génétiquement modifié et son utilisation |
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
JP2008542365A (ja) * | 2005-05-31 | 2008-11-27 | アストラゼネカ・アクチエボラーグ | 新規なmchr1アンタゴニスト並びにmchr1媒介状態及び障害の処置のためのそれらの使用 |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7592358B2 (en) | 2004-04-14 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
US8383647B2 (en) | 2009-01-30 | 2013-02-26 | Takeda Pharmaceutical Company Limited | Quinoline derivative |
US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
US9708337B2 (en) | 2013-02-22 | 2017-07-18 | Bristol-Myers Squibb Company | Aryl amide-based kinase inhibitors |
US10174044B2 (en) | 2015-04-10 | 2019-01-08 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
US10253027B2 (en) | 2013-07-08 | 2019-04-09 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040242572A1 (en) * | 2002-08-24 | 2004-12-02 | Boehringer Ingelheim International Gmbh | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture |
BRPI0407506A (pt) | 2003-02-13 | 2006-02-14 | Wellstat Therapeutics Corp | compostos para o tratamento de distúrbios metabólicos, seu uso e composição farmacêutica compreendendo os mesmos |
CA2517957C (en) * | 2003-03-05 | 2012-01-24 | Toray Industries, Inc. | Aromatic polymer, film, electrolyte membrane and separator |
US20080064729A1 (en) * | 2006-09-07 | 2008-03-13 | Millennium Pharmaceuticals, Inc. | Phenethylamide derivatives with kinase inhibitory activity |
UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
EP2261213A1 (en) * | 2008-04-01 | 2010-12-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20110288142A1 (en) * | 2009-01-30 | 2011-11-24 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
EP2590969B1 (en) | 2010-07-06 | 2014-10-15 | AstraZeneca AB | Therapeutic agents 976 |
JP2014527511A (ja) | 2011-06-24 | 2014-10-16 | アムジエン・インコーポレーテツド | Trpm8拮抗剤及び治療におけるそれらの使用 |
WO2012177896A1 (en) | 2011-06-24 | 2012-12-27 | Amgen Inc. | Trpm8 antagonists and their use in treatments |
UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
US9592186B2 (en) | 2014-09-30 | 2017-03-14 | Avon Products, Inc. | Topical compositions and methods for skin lightening |
WO2016053284A1 (en) * | 2014-09-30 | 2016-04-07 | Avon Products, Inc. | Topical compositions and methods for skin lightening |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021577A2 (en) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
WO2001082925A1 (fr) * | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone concentrant la melanine |
WO2002006245A1 (en) * | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
WO2002051809A1 (en) * | 2000-12-22 | 2002-07-04 | Schering Corporation | Piperidine mch antagonists and their use in the treatment of obesity |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5946214B2 (ja) | 1975-05-29 | 1984-11-10 | ウェルファイド株式会社 | アミノケトン誘導体の製法 |
JPS5939417B2 (ja) | 1975-06-02 | 1984-09-22 | ウェルファイド株式会社 | アミノアルコ−ル誘導体の製法 |
JPS5359675A (en) | 1976-11-08 | 1978-05-29 | Yoshitomi Pharmaceut Ind Ltd | Aminoalcohol derivatives |
DE3063878D1 (en) * | 1979-07-13 | 1983-07-28 | Thomae Gmbh Dr K | Derivatives of carboxylic acids, their preparation and medicaments containing them |
US4562201A (en) * | 1982-07-26 | 1985-12-31 | American Hospital Supply Corporation | Aminomethyl benzanilides |
GB9312893D0 (en) | 1993-06-22 | 1993-08-04 | Boots Co Plc | Therapeutic agents |
DE4438028A1 (de) | 1994-10-25 | 1996-05-02 | Thomae Gmbh Dr K | Basisch substituierte N-Phenylalkyl- und N-Phenoxyalkylamide, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
US6586475B1 (en) | 1998-11-20 | 2003-07-01 | Takeda Chemical Industries, Ltd. | β-amyloid protein production/secretion inhibitors |
JP2001072660A (ja) | 1999-09-08 | 2001-03-21 | Welfide Corp | TNF−α産生抑制剤および/またはIL−10産生促進剤 |
US7183415B2 (en) | 2001-10-25 | 2007-02-27 | Takeda Pharmaceutical Company Limited | Quinoline compound |
DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US20040242572A1 (en) | 2002-08-24 | 2004-12-02 | Boehringer Ingelheim International Gmbh | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture |
-
2004
- 2004-02-12 WO PCT/JP2004/001467 patent/WO2004072018A1/ja not_active Application Discontinuation
- 2004-02-12 EP EP04710515A patent/EP1593667A4/en not_active Withdrawn
- 2004-02-12 US US10/545,120 patent/US7601868B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021577A2 (en) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
WO2001082925A1 (fr) * | 2000-04-28 | 2001-11-08 | Takeda Chemical Industries, Ltd. | Antagonistes de l'hormone concentrant la melanine |
WO2002006245A1 (en) * | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
WO2002051809A1 (en) * | 2000-12-22 | 2002-07-04 | Schering Corporation | Piperidine mch antagonists and their use in the treatment of obesity |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7351719B2 (en) | 2002-10-31 | 2008-04-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds |
US7592373B2 (en) | 2003-12-23 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds |
WO2005063239A1 (de) * | 2003-12-23 | 2005-07-14 | Boehringer Ingelheim International Gmbh | 3-(4-piperidin-1ylmethyl-phenyl) -propionsäure-phrnylamid-derivate und verwandte verbindungen als mch (melanine concentrating hormone) antagonisten zur behandlung von essstörungen |
US7524862B2 (en) | 2004-04-14 | 2009-04-28 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
US7592358B2 (en) | 2004-04-14 | 2009-09-22 | Boehringer Ingelheim International Gmbh | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
WO2006118320A1 (ja) | 2005-04-28 | 2006-11-09 | Takeda Pharmaceutical Company Limited | チエノピリミドン化合物 |
JP2008542365A (ja) * | 2005-05-31 | 2008-11-27 | アストラゼネカ・アクチエボラーグ | 新規なmchr1アンタゴニスト並びにmchr1媒介状態及び障害の処置のためのそれらの使用 |
WO2008001778A1 (fr) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Animal génétiquement modifié et son utilisation |
US8383647B2 (en) | 2009-01-30 | 2013-02-26 | Takeda Pharmaceutical Company Limited | Quinoline derivative |
US8497271B2 (en) | 2009-10-07 | 2013-07-30 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
US8304577B2 (en) | 2009-10-09 | 2012-11-06 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
US8426414B2 (en) | 2009-10-09 | 2013-04-23 | Bristol-Myers Squibb Company | Modulators of G protein-coupled receptor 88 |
US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
US8969564B2 (en) | 2012-03-09 | 2015-03-03 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
US9708337B2 (en) | 2013-02-22 | 2017-07-18 | Bristol-Myers Squibb Company | Aryl amide-based kinase inhibitors |
US10253027B2 (en) | 2013-07-08 | 2019-04-09 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
US10174044B2 (en) | 2015-04-10 | 2019-01-08 | Bristol-Myers Squibb Company | Fused pyridines as kinase inhibitors |
Also Published As
Publication number | Publication date |
---|---|
EP1593667A4 (en) | 2009-03-04 |
US7601868B2 (en) | 2009-10-13 |
US20060128690A1 (en) | 2006-06-15 |
EP1593667A1 (en) | 2005-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004072018A1 (ja) | アミン誘導体 | |
US20050209213A1 (en) | Quinoline compound | |
DE60125026T2 (de) | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung | |
WO2001082925A1 (fr) | Antagonistes de l'hormone concentrant la melanine | |
CN103772239B (zh) | 酰胺和脒衍生物和其用途 | |
WO2001087834A1 (fr) | Antagoniste de l'hormone de concentration de la melanine | |
EP1437351A1 (en) | Amine derivative | |
TW201514157A (zh) | 環丙胺化合物及其用途 | |
WO2001087293A1 (fr) | Inhibiteurs de la ?-secretase | |
WO2001053258A1 (fr) | Composes azotes cycliques et compositions pharmaceutiques les contenant | |
TW200538447A (en) | Compounds having human immunodeficiency virus protease inhibitor activity and the uses thereof | |
AU2006232871A1 (en) | Histamine H3 receptor agents, preparation and therapeutic uses | |
EA018032B1 (ru) | Производные фенилсульфамоилбензамидов в качестве антагонистов брадикининовых рецепторов, способ их получения и фармацевтическая композиция, их содержащая | |
TW201625601A (zh) | 噻吩-2-基-吡啶-2-基-1h-吡唑-4-羧酸衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 | |
WO2000031021A1 (en) | β-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | |
US6627767B2 (en) | Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors | |
WO2000023420A1 (fr) | Derives d'amine aromatique, procede de preparation de ces derives et agents les contenant | |
US20060223826A1 (en) | Indole derivatives as somatostatin agonists or antagonists | |
US4792562A (en) | N-(pyrrol-1-yl)pyridinamines having memory enhancing activity | |
JP4945441B2 (ja) | ヒスタミンh3受容体薬剤、調製、及び治療的使用 | |
JP5057982B2 (ja) | ヒスタミンh3受容体阻害剤、製造及び治療的使用 | |
JP4630555B2 (ja) | アミン誘導体 | |
WO1997011054A1 (en) | Benzoic acid compounds and medicinal use thereof | |
JP2009505961A (ja) | ペプチドデホルミラーゼ阻害剤 | |
EP1870396B1 (en) | Benzyloxypropylamine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006128690 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10545120 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004710515 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004710515 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 10545120 Country of ref document: US |